[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$faM3NvWNnCmPFnFmthSQtRtBs1S0GebGd-tx2b7TSG1w":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":83,"rows":90},"Bausch Health Americas, Inc.",[4],212,false,16,85,78058,15,14,[14,17,19,21,24,27,29,32],{"name":15,"count":16},"Acne Vulgaris",21,{"name":18,"count":8},"Psoriasis",{"name":20,"count":12},"Ulcerative Colitis",{"name":22,"count":23},"Constipation",9,{"name":25,"count":26},"Plaque Psoriasis",7,{"name":28,"count":26},"Chronic Idiopathic Constipation",{"name":30,"count":31},"Acne",6,{"name":33,"count":31},"Healthy",[35,40,45,49,54,59,64,69,74,79],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05132231","Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity","2025-02-05","Brodalumab",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05071716","Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis","2025-09","Rifaximin SSD",{"nctId":46,"briefTitle":47,"date":48,"intervention":44},"NCT05297448","Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis","2026-01",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03987763","A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis","2026-05","IDP-122 Lotion",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT07205107","Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris","2026-08","clindamycin phosphate, adapalene and benzoyl peroxide",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04314375","Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis","2026-12","Low Dose Budesonide",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT07285785","Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea","2027-04-20","Rifaximin 200 mg",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT07428538","Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)","2027-11","Larsucosterol",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT07524946","Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo","2027-12","CABTREO is a fixed-combination product of clindamycin phosphate 1.2%\u002FBPO 3.1%\u002Fadapalene 0.15%.",{"nctId":80,"briefTitle":81,"date":77,"intervention":82},"NCT00568997","10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus","Pimecrolimus",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,167,220,242,260,285,303,322,346,371,398,420,440,462,480,498,629,720,783,837,875,904,931,949,967,992,1010,1035,1060,1078,1096,1114,1139,1157,1276,1354,1419,1453,1514,1548,1578,1621,1675,1702,1740,1785,1827,1853,1896,1926,1966,1999,2033,2057,2085,2118,2140,2172,2194,2223,2245,2267,2293,2311,2329,2347,2371,2395,2421,2439,2457,2482,2500,2518,2536,2561,2579,2606,2624,2642,2667,2688,2712,2734,2760,2778,2801,2826,2844,2862,2886,2904,2930,2948,2966,2989,3046,3076,3102,3124,3159,3189,3211,3239,3257,3275,3293,3311,3329,3358,3376,3394,3412,3430,3454,3472,3490,3516,3534,3552,3570,3592,3620,3638,3656,3674,3692,3715,3733,3757,3775,3798,3821,3846,3872,3890,3908,3936,3954,3972,3990,4008,4026,4044,4062,4080,4098,4123,4141,4159,4177,4195,4213,4231,4249,4274,4292,4310,4335,4353,4371,4389,4423,4445,4469,4487,4510,4534,4552,4570,4591,4617,4635,4653,4678,4700,4718,4736,4760,4778,4803,4821,4919,5021,5051,5069],{"intervention":39,"totalTrials":31,"cells":92},{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":118,"PHASE3":120,"PHASE4":122,"NA":136},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[98,109],{"nctId":99,"briefTitle":100,"status":101,"phases":102,"primaryCompletion":103,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":108},"NCT01937260","Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects","COMPLETED",[85],"2014-07","2014-12","2013-09",31,[18],[39],{"nctId":110,"briefTitle":111,"status":101,"phases":112,"primaryCompletion":113,"completion":104,"start":114,"enrollment":115,"conditions":116,"interventions":117},"NCT02173392","A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab",[85],"2014-11","2014-09",145,[18],[39],{"trials":119,"activeCount":95},[],{"trials":121,"activeCount":95},[],{"trials":123,"activeCount":135,"soonestReadout":129},[124],{"nctId":125,"briefTitle":126,"status":127,"phases":128,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":134},"NCT03240809","An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects","ACTIVE_NOT_RECRUITING",[88],"2028-12","2029-06","2020-01-24",2,[18],[39,39],1,{"trials":137,"activeCount":132,"soonestReadout":38},[138,147,159],{"nctId":139,"briefTitle":140,"status":101,"phases":141,"primaryCompletion":142,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":146},"NCT04149587","A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen",[],"2022-03-30","2019-09-30",252,[18],[39],{"nctId":148,"briefTitle":149,"status":150,"phases":151,"primaryCompletion":152,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":157},"NCT03254667","LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis","ENROLLING_BY_INVITATION",[],"2030-11-10","2031-11","2017-07-25",3500,[18],[39,158],"Comparator Drug",{"nctId":36,"briefTitle":37,"status":127,"phases":160,"primaryCompletion":38,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":165},[],"2026-03-31","2021-10-22",394,[18],[39,166],"Matched cohort",{"intervention":53,"totalTrials":168,"cells":169},4,{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":189,"PHASE4":208,"NA":218},{"trials":171,"activeCount":95},[],{"trials":173,"activeCount":95},[],{"trials":175,"activeCount":95},[176],{"nctId":177,"briefTitle":178,"status":101,"phases":179,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":185},"NCT02785185","Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis",[86],"2016-12-02","2017-01","2016-06",150,[18],[186,187,53,188],"IDP-122 Vehicle Lotion","IDP-122 Vehicle Cream","Ultravate Cream",{"trials":190,"activeCount":95},[191,200],{"nctId":192,"briefTitle":193,"status":101,"phases":194,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":199},"NCT02514577","Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis",[87],"2017-05-01","2015-11-07",217,[25],[53,186],{"nctId":201,"briefTitle":193,"status":101,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":207},"NCT02515097",[87],"2017-03-15","2015-11-05",213,[25],[53,186],{"trials":209,"activeCount":135,"soonestReadout":52},[210],{"nctId":50,"briefTitle":51,"status":211,"phases":212,"primaryCompletion":52,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":217},"RECRUITING",[88],"2026-06","2019-10-22",45,[18],[53],{"trials":219,"activeCount":95},[],{"intervention":63,"totalTrials":135,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":240},{"trials":223,"activeCount":95},[],{"trials":225,"activeCount":95},[],{"trials":227,"activeCount":95},[],{"trials":229,"activeCount":95},[],{"trials":231,"activeCount":135,"soonestReadout":62},[232],{"nctId":60,"briefTitle":61,"status":211,"phases":233,"primaryCompletion":62,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":238},[88],"2027-06","2023-09-29",70,[20],[63,239],"High Dose Budesonide",{"trials":241,"activeCount":95},[],{"intervention":239,"totalTrials":135,"cells":243},{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":250,"PHASE4":252,"NA":258},{"trials":245,"activeCount":95},[],{"trials":247,"activeCount":95},[],{"trials":249,"activeCount":95},[],{"trials":251,"activeCount":95},[],{"trials":253,"activeCount":135,"soonestReadout":62},[254],{"nctId":60,"briefTitle":61,"status":211,"phases":255,"primaryCompletion":62,"completion":234,"start":235,"enrollment":236,"conditions":256,"interventions":257},[88],[20],[63,239],{"trials":259,"activeCount":95},[],{"intervention":261,"totalTrials":135,"cells":262},"High dose budesonide rectal foam",{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":269,"PHASE4":271,"NA":283},{"trials":264,"activeCount":95},[],{"trials":266,"activeCount":95},[],{"trials":268,"activeCount":95},[],{"trials":270,"activeCount":95},[],{"trials":272,"activeCount":135,"soonestReadout":130},[273],{"nctId":274,"briefTitle":275,"status":276,"phases":277,"primaryCompletion":130,"completion":278,"start":234,"enrollment":279,"conditions":280,"interventions":281},"NCT05976802","Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis","NOT_YET_RECRUITING",[88],"2030-01",100,[20],[261,282],"Low dose budesonide rectal foam",{"trials":284,"activeCount":95},[],{"intervention":282,"totalTrials":135,"cells":286},{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":293,"PHASE4":295,"NA":301},{"trials":288,"activeCount":95},[],{"trials":290,"activeCount":95},[],{"trials":292,"activeCount":95},[],{"trials":294,"activeCount":95},[],{"trials":296,"activeCount":135,"soonestReadout":130},[297],{"nctId":274,"briefTitle":275,"status":276,"phases":298,"primaryCompletion":130,"completion":278,"start":234,"enrollment":279,"conditions":299,"interventions":300},[88],[20],[261,282],{"trials":302,"activeCount":95},[],{"intervention":78,"totalTrials":135,"cells":304},{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":313,"NA":320},{"trials":306,"activeCount":95},[],{"trials":308,"activeCount":95},[],{"trials":310,"activeCount":95},[],{"trials":312,"activeCount":95},[],{"trials":314,"activeCount":135,"soonestReadout":77},[315],{"nctId":75,"briefTitle":76,"status":276,"phases":316,"primaryCompletion":77,"completion":77,"start":317,"enrollment":279,"conditions":318,"interventions":319},[88],"2026-04",[15],[78],{"trials":321,"activeCount":95},[],{"intervention":68,"totalTrials":135,"cells":323},{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":332,"NA":344},{"trials":325,"activeCount":95},[],{"trials":327,"activeCount":95},[],{"trials":329,"activeCount":95},[],{"trials":331,"activeCount":95},[],{"trials":333,"activeCount":135,"soonestReadout":67},[334],{"nctId":65,"briefTitle":66,"status":211,"phases":335,"primaryCompletion":67,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":343},[88],"2027-07-31","2026-02-11",54,[340,341,342],"Diarrhea","Gastroenteritis","Bacterial Infection",[68],{"trials":345,"activeCount":95},[],{"intervention":347,"totalTrials":135,"cells":348},"bupropion hydrobromide",{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":369},{"trials":350,"activeCount":95},[],{"trials":352,"activeCount":95},[],{"trials":354,"activeCount":95},[],{"trials":356,"activeCount":95},[],{"trials":358,"activeCount":135,"soonestReadout":363},[359],{"nctId":360,"briefTitle":361,"status":276,"phases":362,"primaryCompletion":363,"completion":364,"start":213,"enrollment":365,"conditions":366,"interventions":368},"NCT02129751","Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder",[88],"2029-07","2029-12",246,[367],"Major Depressive Disorder",[347],{"trials":370,"activeCount":95},[],{"intervention":44,"totalTrials":132,"cells":372},{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":379,"PHASE4":394,"NA":396},{"trials":374,"activeCount":95},[],{"trials":376,"activeCount":95},[],{"trials":378,"activeCount":95},[],{"trials":380,"activeCount":132,"soonestReadout":43},[381,388],{"nctId":41,"briefTitle":42,"status":127,"phases":382,"primaryCompletion":43,"completion":43,"start":383,"enrollment":384,"conditions":385,"interventions":387},[87],"2022-04-07",524,[386],"Hepatic Encephalopathy",[44],{"nctId":46,"briefTitle":47,"status":127,"phases":389,"primaryCompletion":48,"completion":48,"start":390,"enrollment":391,"conditions":392,"interventions":393},[87],"2022-08-03",466,[386],[44],{"trials":395,"activeCount":95},[],{"trials":397,"activeCount":95},[],{"intervention":73,"totalTrials":135,"cells":399},{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":406,"PHASE4":416,"NA":418},{"trials":401,"activeCount":95},[],{"trials":403,"activeCount":95},[],{"trials":405,"activeCount":95},[],{"trials":407,"activeCount":135,"soonestReadout":72},[408],{"nctId":70,"briefTitle":71,"status":211,"phases":409,"primaryCompletion":72,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":415},[87],"2028-02","2026-01-29",350,[414],"Hepatitis",[73],{"trials":417,"activeCount":95},[],{"trials":419,"activeCount":95},[],{"intervention":58,"totalTrials":135,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":430,"NA":432},{"trials":423,"activeCount":95},[],{"trials":425,"activeCount":95},[],{"trials":427,"activeCount":95},[],{"trials":429,"activeCount":95},[],{"trials":431,"activeCount":95},[],{"trials":433,"activeCount":135,"soonestReadout":57},[434],{"nctId":55,"briefTitle":56,"status":127,"phases":435,"primaryCompletion":57,"completion":57,"start":436,"enrollment":437,"conditions":438,"interventions":439},[],"2025-10-02",200,[15],[58],{"intervention":82,"totalTrials":135,"cells":441},{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":450,"NA":452},{"trials":443,"activeCount":95},[],{"trials":445,"activeCount":95},[],{"trials":447,"activeCount":95},[],{"trials":449,"activeCount":95},[],{"trials":451,"activeCount":95},[],{"trials":453,"activeCount":135,"soonestReadout":77},[454],{"nctId":80,"briefTitle":81,"status":127,"phases":455,"primaryCompletion":77,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":461},[],"2028-06","2005-06-27",8000,[460],"Atopic Dermatitis",[82],{"intervention":158,"totalTrials":135,"cells":463},{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":472,"NA":474},{"trials":465,"activeCount":95},[],{"trials":467,"activeCount":95},[],{"trials":469,"activeCount":95},[],{"trials":471,"activeCount":95},[],{"trials":473,"activeCount":95},[],{"trials":475,"activeCount":135,"soonestReadout":152},[476],{"nctId":148,"briefTitle":149,"status":150,"phases":477,"primaryCompletion":152,"completion":153,"start":154,"enrollment":155,"conditions":478,"interventions":479},[],[18],[39,158],{"intervention":166,"totalTrials":135,"cells":481},{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":490,"NA":492},{"trials":483,"activeCount":95},[],{"trials":485,"activeCount":95},[],{"trials":487,"activeCount":95},[],{"trials":489,"activeCount":95},[],{"trials":491,"activeCount":95},[],{"trials":493,"activeCount":135,"soonestReadout":38},[494],{"nctId":36,"briefTitle":37,"status":127,"phases":495,"primaryCompletion":38,"completion":161,"start":162,"enrollment":163,"conditions":496,"interventions":497},[],[18],[39,166],{"intervention":499,"totalTrials":500,"cells":501},"Rifaximin",12,{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":518,"PHASE3":530,"PHASE4":595,"NA":627},{"trials":503,"activeCount":95},[],{"trials":505,"activeCount":95},[506],{"nctId":507,"briefTitle":508,"status":101,"phases":509,"primaryCompletion":510,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":516},"NCT00743912","Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers",[85],"2008-10","2008-11","2008-09",24,[515],"Pharmacokinetic",[517],"rifaximin",{"trials":519,"activeCount":95},[520],{"nctId":521,"briefTitle":522,"status":101,"phases":523,"primaryCompletion":524,"completion":512,"start":525,"enrollment":526,"conditions":527,"interventions":529},"NCT00269412","Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome",[86],"2007-08","2005-12",525,[528],"Irritable Bowel Syndrome",[499],{"trials":531,"activeCount":95},[532,541,551,562,570,576,585],{"nctId":533,"briefTitle":534,"status":101,"phases":535,"primaryCompletion":536,"completion":536,"start":537,"enrollment":538,"conditions":539,"interventions":540},"NCT00686920","Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy",[87],"2010-12-08","2007-03-07",322,[386],[499],{"nctId":542,"briefTitle":543,"status":101,"phases":544,"primaryCompletion":545,"completion":545,"start":525,"enrollment":546,"conditions":547,"interventions":549},"NCT00269399","A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)",[87],"2008-12",237,[548,340],"Clostridium Infections",[499,550],"Vancomycin",{"nctId":552,"briefTitle":553,"status":101,"phases":554,"primaryCompletion":555,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":561},"NCT00724126","Rifaximin 3 Times\u002FDay (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)",[87],"2009-08","2009-09","2008-07",637,[560],"Non-Constipation Irritable Bowel Syndrome",[499],{"nctId":563,"briefTitle":564,"status":101,"phases":565,"primaryCompletion":566,"completion":512,"start":525,"enrollment":567,"conditions":568,"interventions":569},"NCT00328380","Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.",[87],"2006-12",660,[340],[499],{"nctId":571,"briefTitle":553,"status":101,"phases":572,"primaryCompletion":555,"completion":556,"start":557,"enrollment":573,"conditions":574,"interventions":575},"NCT00731679",[87],623,[560],[499],{"nctId":577,"briefTitle":578,"status":101,"phases":579,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":584},"NCT00298038","A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy",[87],"2008-08-15","2005-12-19",299,[386],[499],{"nctId":586,"briefTitle":587,"status":101,"phases":588,"primaryCompletion":589,"completion":590,"start":591,"enrollment":592,"conditions":593,"interventions":594},"NCT00742469","Rifaximin for Prevention of Travellers' Diarrhea",[87],"2005-09","2007-04","2005-06",210,[340],[499],{"trials":596,"activeCount":95},[597,608,619],{"nctId":598,"briefTitle":599,"status":600,"phases":601,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":605,"interventions":607},"NCT03818672","Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects","TERMINATED",[88],"2020-02-02","2019-01-29",5,[606],"Severe Hepatic Impairment",[499],{"nctId":609,"briefTitle":610,"status":101,"phases":611,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":617},"NCT01842581","The Safety\u002FEfficacy of Rifaximin With\u002FWithout Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy",[88],"2014-12-17","2013-01-08",222,[386,616],"Cirrhosis",[499,618],"Lactulose",{"nctId":620,"briefTitle":621,"status":600,"phases":622,"primaryCompletion":623,"completion":623,"start":624,"enrollment":31,"conditions":625,"interventions":626},"NCT01846663","Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy",[88],"2016-02-22","2013-04-03",[386],[499],{"trials":628,"activeCount":95},[],{"intervention":630,"totalTrials":631,"cells":632},"IDP-118 Lotion",8,{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":648,"PHASE3":678,"PHASE4":708,"NA":718},{"trials":634,"activeCount":95},[],{"trials":636,"activeCount":95},[637],{"nctId":638,"briefTitle":639,"status":101,"phases":640,"primaryCompletion":641,"completion":181,"start":642,"enrollment":643,"conditions":644,"interventions":645},"NCT03058744","Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis",[85],"2016-12","2015-04",94,[18],[630,646,188,647],"HP Monad Lotion","Tazorac Cream",{"trials":649,"activeCount":95},[650,660,669],{"nctId":651,"briefTitle":652,"status":101,"phases":653,"primaryCompletion":641,"completion":181,"start":654,"enrollment":655,"conditions":656,"interventions":657},"NCT02785172","Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis",[86],"2016-04",154,[18],[658,659,630,188],"IDP-118 Vehicle Lotion","IDP-118 Vehicle Cream",{"nctId":661,"briefTitle":662,"status":101,"phases":663,"primaryCompletion":664,"completion":641,"start":665,"enrollment":666,"conditions":667,"interventions":668},"NCT02785159","Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis",[86],"2016-11-20","2016-02",152,[18],[630,647,658,659],{"nctId":670,"briefTitle":671,"status":101,"phases":672,"primaryCompletion":113,"completion":113,"start":673,"enrollment":6,"conditions":674,"interventions":675},"NCT02045277","Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis",[86],"2014-02",[25],[630,676,677,658],"IDP-118 Monad HP Lotion","IDP-118 Monad Taz Lotion",{"trials":679,"activeCount":95},[680,690,699],{"nctId":681,"briefTitle":682,"status":101,"phases":683,"primaryCompletion":684,"completion":685,"start":686,"enrollment":687,"conditions":688,"interventions":689},"NCT02462083","Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis",[87],"2017-01-31","2017-04-24","2015-08-11",555,[25],[630],{"nctId":691,"briefTitle":692,"status":101,"phases":693,"primaryCompletion":694,"completion":695,"start":686,"enrollment":696,"conditions":697,"interventions":698},"NCT02462070","Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis",[87],"2016-11-08","2016-12-01",203,[25],[630,658],{"nctId":700,"briefTitle":692,"status":101,"phases":701,"primaryCompletion":702,"completion":703,"start":704,"enrollment":705,"conditions":706,"interventions":707},"NCT02462122",[87],"2016-11-09","2016-11-14","2015-08-19",215,[25],[630,658],{"trials":709,"activeCount":95},[710],{"nctId":711,"briefTitle":712,"status":101,"phases":713,"primaryCompletion":714,"completion":714,"start":715,"enrollment":8,"conditions":716,"interventions":717},"NCT03988439","A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis",[88],"2026-02-06","2021-03-24",[18],[630],{"trials":719,"activeCount":95},[],{"intervention":721,"totalTrials":604,"cells":722},"Methylnaltrexone bromide",{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":737,"PHASE3":749,"PHASE4":769,"NA":781},{"trials":724,"activeCount":95},[],{"trials":726,"activeCount":95},[727],{"nctId":728,"briefTitle":729,"status":101,"phases":730,"primaryCompletion":731,"completion":731,"start":732,"enrollment":733,"conditions":734,"interventions":736},"NCT01366326","Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects",[85],"2010-08","2010-07",20,[735],"Healthy Adult Subjects",[721],{"trials":738,"activeCount":95},[739],{"nctId":740,"briefTitle":741,"status":101,"phases":742,"primaryCompletion":743,"completion":743,"start":744,"enrollment":745,"conditions":746,"interventions":748},"NCT00640146","Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures",[86],"2009-01-21","2007-10-19",37,[747],"Opioid-induced Constipation",[721],{"trials":750,"activeCount":95},[751,761],{"nctId":752,"briefTitle":753,"status":754,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":95,"conditions":758,"interventions":760},"NCT04151719","An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer","WITHDRAWN",[87],"2024-02-03","2020-02-03",[759],"Pancreatic Cancer",[721],{"nctId":762,"briefTitle":763,"status":754,"phases":764,"primaryCompletion":765,"completion":765,"start":766,"enrollment":95,"conditions":767,"interventions":768},"NCT04083651","A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer",[86,87],"2023-10-15","2020-01-06",[759],[721],{"trials":770,"activeCount":95},[771],{"nctId":772,"briefTitle":773,"status":101,"phases":774,"primaryCompletion":775,"completion":776,"start":557,"enrollment":777,"conditions":778,"interventions":780},"NCT00672139","Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness",[88],"2013-01","2013-05",156,[779],"Opioid-Induced Constipation",[721],{"trials":782,"activeCount":95},[],{"intervention":784,"totalTrials":168,"cells":785},"Tretinoin Gel",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":792,"PHASE4":794,"NA":835},{"trials":787,"activeCount":95},[],{"trials":789,"activeCount":95},[],{"trials":791,"activeCount":95},[],{"trials":793,"activeCount":95},[],{"trials":795,"activeCount":95},[796,806,816,826],{"nctId":797,"briefTitle":798,"status":101,"phases":799,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":803,"interventions":804},"NCT00714714","Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.",[88],"2008-02","2008-01",25,[15],[805,784],"Adapalene Gel",{"nctId":807,"briefTitle":808,"status":101,"phases":809,"primaryCompletion":556,"completion":556,"start":810,"enrollment":811,"conditions":812,"interventions":813},"NCT00907257","A Study of Different Use Regimens Using Two Acne Treatments",[88],"2009-02",247,[15],[814,815],"benzoyl peroxide wash","Tretinoin gel",{"nctId":817,"briefTitle":818,"status":101,"phases":819,"primaryCompletion":820,"completion":821,"start":820,"enrollment":822,"conditions":823,"interventions":824},"NCT01313728","A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products",[88],"2010-12","2011-01",26,[15],[825,784],"Dapsone plus Tretinoin Gel",{"nctId":827,"briefTitle":828,"status":101,"phases":829,"primaryCompletion":830,"completion":830,"start":831,"enrollment":822,"conditions":832,"interventions":833},"NCT00919191","Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face",[88],"2009-05","2009-04",[15],[815,834],"Adapalene and Benzoyl peroxide",{"trials":836,"activeCount":95},[],{"intervention":838,"totalTrials":132,"cells":839},"Luliconazole Cream 1%",{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":844,"PHASE3":846,"PHASE4":848,"NA":873},{"trials":841,"activeCount":95},[],{"trials":843,"activeCount":95},[],{"trials":845,"activeCount":95},[],{"trials":847,"activeCount":95},[],{"trials":849,"activeCount":95},[850,862],{"nctId":851,"briefTitle":852,"status":101,"phases":853,"primaryCompletion":854,"completion":855,"start":856,"enrollment":857,"conditions":858,"interventions":860},"NCT02767947","Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis",[88],"2016-06-29","2016-09-22","2016-02-08",75,[859],"Tinea Corporis",[838,861],"Vehicle Cream",{"nctId":863,"briefTitle":864,"status":101,"phases":865,"primaryCompletion":866,"completion":866,"start":867,"enrollment":868,"conditions":869,"interventions":872},"NCT02767271","Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris",[88],"2016-04-27","2015-12-02",30,[870,871],"Tinea Pedis","Tinea Cruris",[838],{"trials":874,"activeCount":95},[],{"intervention":861,"totalTrials":132,"cells":876},{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":894,"PHASE4":896,"NA":902},{"trials":878,"activeCount":95},[],{"trials":880,"activeCount":95},[],{"trials":882,"activeCount":95},[883],{"nctId":884,"briefTitle":885,"status":101,"phases":886,"primaryCompletion":887,"completion":888,"start":889,"enrollment":592,"conditions":890,"interventions":891},"NCT02938494","Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris",[86],"2016-07","2016-09","2015-11",[15],[892,647,893,861],"IDP-123 Lotion","Vehicle Lotion",{"trials":895,"activeCount":95},[],{"trials":897,"activeCount":95},[898],{"nctId":851,"briefTitle":852,"status":101,"phases":899,"primaryCompletion":854,"completion":855,"start":856,"enrollment":857,"conditions":900,"interventions":901},[88],[859],[838,861],{"trials":903,"activeCount":95},[],{"intervention":905,"totalTrials":135,"cells":906},"Polyethylene glycol",{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":915,"NA":929},{"trials":908,"activeCount":95},[],{"trials":910,"activeCount":95},[],{"trials":912,"activeCount":95},[],{"trials":914,"activeCount":95},[],{"trials":916,"activeCount":95},[917],{"nctId":918,"briefTitle":919,"status":101,"phases":920,"primaryCompletion":921,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":927},"NCT01427296","Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing",[88],"2014-03-11","2014-12-09","2011-09-16",2154,[926],"Colon Cleansing",[905,928],"Oral sodium phosphate solution",{"trials":930,"activeCount":95},[],{"intervention":928,"totalTrials":135,"cells":932},{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":939,"PHASE4":941,"NA":947},{"trials":934,"activeCount":95},[],{"trials":936,"activeCount":95},[],{"trials":938,"activeCount":95},[],{"trials":940,"activeCount":95},[],{"trials":942,"activeCount":95},[943],{"nctId":918,"briefTitle":919,"status":101,"phases":944,"primaryCompletion":921,"completion":922,"start":923,"enrollment":924,"conditions":945,"interventions":946},[88],[926],[905,928],{"trials":948,"activeCount":95},[],{"intervention":618,"totalTrials":135,"cells":950},{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":965},{"trials":952,"activeCount":95},[],{"trials":954,"activeCount":95},[],{"trials":956,"activeCount":95},[],{"trials":958,"activeCount":95},[],{"trials":960,"activeCount":95},[961],{"nctId":609,"briefTitle":610,"status":101,"phases":962,"primaryCompletion":612,"completion":612,"start":613,"enrollment":614,"conditions":963,"interventions":964},[88],[386,616],[499,618],{"trials":966,"activeCount":95},[],{"intervention":968,"totalTrials":135,"cells":969},"Bexarotene",{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":978,"NA":990},{"trials":971,"activeCount":95},[],{"trials":973,"activeCount":95},[],{"trials":975,"activeCount":95},[],{"trials":977,"activeCount":95},[],{"trials":979,"activeCount":95},[980],{"nctId":981,"briefTitle":982,"status":101,"phases":983,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":987,"interventions":989},"NCT01007448","Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)",[88],"2014-02-20","2010-01-06",59,[988],"Refractory Cutaneous T-cell Lymphoma",[968],{"trials":991,"activeCount":95},[],{"intervention":805,"totalTrials":135,"cells":993},{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":998,"PHASE3":1000,"PHASE4":1002,"NA":1008},{"trials":995,"activeCount":95},[],{"trials":997,"activeCount":95},[],{"trials":999,"activeCount":95},[],{"trials":1001,"activeCount":95},[],{"trials":1003,"activeCount":95},[1004],{"nctId":797,"briefTitle":798,"status":101,"phases":1005,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":1006,"interventions":1007},[88],[15],[805,784],{"trials":1009,"activeCount":95},[],{"intervention":1011,"totalTrials":135,"cells":1012},"Poly-L-Lactic Acid",{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1019,"PHASE4":1021,"NA":1033},{"trials":1014,"activeCount":95},[],{"trials":1016,"activeCount":95},[],{"trials":1018,"activeCount":95},[],{"trials":1020,"activeCount":95},[],{"trials":1022,"activeCount":95},[1023],{"nctId":1024,"briefTitle":1025,"status":101,"phases":1026,"primaryCompletion":1027,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1032},"NCT00447551","Canadian Aesthetic Experience With Sculptra Therapy",[88],"2008-04","2007-01",76,[1031],"Skin Aging",[1011],{"trials":1034,"activeCount":95},[],{"intervention":1036,"totalTrials":135,"cells":1037},"Tretinoin Facial Gel",{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1044,"PHASE4":1046,"NA":1058},{"trials":1039,"activeCount":95},[],{"trials":1041,"activeCount":95},[],{"trials":1043,"activeCount":95},[],{"trials":1045,"activeCount":95},[],{"trials":1047,"activeCount":95},[1048],{"nctId":1049,"briefTitle":1050,"status":101,"phases":1051,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1056},"NCT00952523","Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face",[88],"2009-10","2009-07",162,[15],[1036,1057],"Adapalene\u002FBenzoyl Peroxide Facial Gel",{"trials":1059,"activeCount":95},[],{"intervention":1057,"totalTrials":135,"cells":1061},{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1068,"PHASE4":1070,"NA":1076},{"trials":1063,"activeCount":95},[],{"trials":1065,"activeCount":95},[],{"trials":1067,"activeCount":95},[],{"trials":1069,"activeCount":95},[],{"trials":1071,"activeCount":95},[1072],{"nctId":1049,"briefTitle":1050,"status":101,"phases":1073,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":1074,"interventions":1075},[88],[15],[1036,1057],{"trials":1077,"activeCount":95},[],{"intervention":814,"totalTrials":135,"cells":1079},{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1084,"PHASE3":1086,"PHASE4":1088,"NA":1094},{"trials":1081,"activeCount":95},[],{"trials":1083,"activeCount":95},[],{"trials":1085,"activeCount":95},[],{"trials":1087,"activeCount":95},[],{"trials":1089,"activeCount":95},[1090],{"nctId":807,"briefTitle":808,"status":101,"phases":1091,"primaryCompletion":556,"completion":556,"start":810,"enrollment":811,"conditions":1092,"interventions":1093},[88],[15],[814,815],{"trials":1095,"activeCount":95},[],{"intervention":825,"totalTrials":135,"cells":1097},{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1112},{"trials":1099,"activeCount":95},[],{"trials":1101,"activeCount":95},[],{"trials":1103,"activeCount":95},[],{"trials":1105,"activeCount":95},[],{"trials":1107,"activeCount":95},[1108],{"nctId":817,"briefTitle":818,"status":101,"phases":1109,"primaryCompletion":820,"completion":821,"start":820,"enrollment":822,"conditions":1110,"interventions":1111},[88],[15],[825,784],{"trials":1113,"activeCount":95},[],{"intervention":1115,"totalTrials":135,"cells":1116},"Efinaconazole",{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1123,"PHASE4":1125,"NA":1137},{"trials":1118,"activeCount":95},[],{"trials":1120,"activeCount":95},[],{"trials":1122,"activeCount":95},[],{"trials":1124,"activeCount":95},[],{"trials":1126,"activeCount":95},[1127],{"nctId":1128,"briefTitle":1129,"status":101,"phases":1130,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1136},"NCT02812771","Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis",[88],"2019-01-14","2016-08-04",62,[1135],"Onychomycosis",[1115],{"trials":1138,"activeCount":95},[],{"intervention":834,"totalTrials":135,"cells":1140},{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1147,"PHASE4":1149,"NA":1155},{"trials":1142,"activeCount":95},[],{"trials":1144,"activeCount":95},[],{"trials":1146,"activeCount":95},[],{"trials":1148,"activeCount":95},[],{"trials":1150,"activeCount":95},[1151],{"nctId":827,"briefTitle":828,"status":101,"phases":1152,"primaryCompletion":830,"completion":830,"start":831,"enrollment":822,"conditions":1153,"interventions":1154},[88],[15],[815,834],{"trials":1156,"activeCount":95},[],{"intervention":1158,"totalTrials":1159,"cells":1160},"MOA-728",13,{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1243,"PHASE3":1260,"PHASE4":1272,"NA":1274},{"trials":1162,"activeCount":95},[],{"trials":1164,"activeCount":95},[1165,1173,1182,1191,1198,1206,1213,1219,1227,1236],{"nctId":1166,"briefTitle":1167,"status":101,"phases":1168,"completion":1169,"start":590,"enrollment":1170,"conditions":1171,"interventions":1172},"NCT00464802","Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects",[85],"2007-06",36,[33],[1158],{"nctId":1174,"briefTitle":1175,"status":101,"phases":1176,"primaryCompletion":1177,"completion":1177,"start":1178,"enrollment":8,"conditions":1179,"interventions":1181},"NCT00387491","Dose Ranging Study in Healthy Methadone Maintenance Subjects",[85],"2006-10","2006-06",[1180],"Adult",[1158],{"nctId":1183,"briefTitle":1184,"status":754,"phases":1185,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":95,"conditions":1188,"interventions":1190},"NCT00505583","Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy",[85],"2007-12","2007-07",[1189],"Methadone-maintenance Subjects",[1158],{"nctId":1192,"briefTitle":1193,"status":101,"phases":1194,"completion":566,"start":1177,"conditions":1195,"interventions":1197},"NCT00398502","Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations Of MOA-728 In Subjects On Methadone",[85],[1196],"Metahdone-maintenance Subjects",[1158],{"nctId":1199,"briefTitle":1200,"status":101,"phases":1201,"completion":1202,"start":1203,"conditions":1204,"interventions":1205},"NCT00447811","Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance",[85],"2007-05","2007-03",[1189],[1158],{"nctId":1207,"briefTitle":1208,"status":101,"phases":1209,"completion":1210,"start":1203,"conditions":1211,"interventions":1212},"NCT00434395","Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects",[85],"2007-10",[33],[1158],{"nctId":1214,"briefTitle":1215,"status":101,"phases":1216,"completion":1187,"start":1203,"enrollment":513,"conditions":1217,"interventions":1218},"NCT00444158","Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour IV of MOA-728 in Stable Methadone Subjects",[85],[22],[1158],{"nctId":1220,"briefTitle":1221,"status":101,"phases":1222,"primaryCompletion":1223,"completion":1223,"start":1224,"conditions":1225,"interventions":1226},"NCT00387985","Bioequivalence Study in Healthy Volunteers",[85],"2006-09","2006-08",[33],[1158],{"nctId":1228,"briefTitle":1229,"status":101,"phases":1230,"completion":1224,"start":1231,"enrollment":1232,"conditions":1233,"interventions":1235},"NCT00311350","Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects",[85],"2006-03",48,[1234,22],"Postoperative Complications",[1158],{"nctId":1237,"briefTitle":1238,"status":754,"phases":1239,"start":1240,"enrollment":95,"conditions":1241,"interventions":1242},"NCT00427258","Study Evaluating MOA-728 Administered in Healthy Men",[85],"2010-01",[33],[1158],{"trials":1244,"activeCount":95},[1245,1252],{"nctId":1246,"briefTitle":1247,"status":101,"phases":1248,"completion":1203,"start":1224,"enrollment":1249,"conditions":1250,"interventions":1251},"NCT00366431","Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain",[86],420,[22],[1158],{"nctId":1253,"briefTitle":1254,"status":101,"phases":1255,"primaryCompletion":1256,"completion":1256,"start":801,"enrollment":1257,"conditions":1258,"interventions":1259},"NCT00605644","Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain",[86],"2008-05",128,[22],[1158],{"trials":1261,"activeCount":95},[1262],{"nctId":1263,"briefTitle":1264,"status":101,"phases":1265,"primaryCompletion":1266,"completion":1266,"start":1267,"enrollment":1268,"conditions":1269,"interventions":1271},"NCT00528970","A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair",[87],"2008-02-05","2007-10-17",374,[1270],"Ileus",[1158],{"trials":1273,"activeCount":95},[],{"trials":1275,"activeCount":95},[],{"intervention":1277,"totalTrials":26,"cells":1278},"SC Methylnaltrexone",{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1311,"PHASE3":1313,"PHASE4":1350,"NA":1352},{"trials":1280,"activeCount":95},[],{"trials":1282,"activeCount":95},[1283,1292,1302],{"nctId":1284,"briefTitle":1285,"status":101,"phases":1286,"primaryCompletion":1287,"completion":1287,"start":1288,"enrollment":513,"conditions":1289,"interventions":1291},"NCT01367522","Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function",[85],"2004-07","2004-03",[1290],"Liver Dysfunction",[1277],{"nctId":1293,"briefTitle":1294,"status":101,"phases":1295,"primaryCompletion":1224,"completion":1224,"start":1231,"enrollment":338,"conditions":1296,"interventions":1298},"NCT01367535","Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan",[85],[1297],"Healthy Adults",[1277,1299,1300,1301],"IV Methylnaltrexone","Oral Paroxetine","SC Placebo",{"nctId":1303,"briefTitle":1304,"status":101,"phases":1305,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":31,"conditions":1308,"interventions":1310},"NCT01367496","Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose",[85],"2002-08","2002-06",[1309],"Healthy Subjects",[1277,1277,1277,1299],{"trials":1312,"activeCount":95},[],{"trials":1314,"activeCount":95},[1315,1324,1333,1340],{"nctId":1316,"briefTitle":1317,"status":101,"phases":1318,"primaryCompletion":1319,"completion":1319,"start":1320,"enrollment":655,"conditions":1321,"interventions":1323},"NCT00401362","A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients",[87],"2005-02","2003-02",[1322],"Advanced Illness Patients With Opioid Induced Constipation",[1277,1301,1277],{"nctId":1325,"briefTitle":1326,"status":101,"phases":1327,"primaryCompletion":1328,"completion":1328,"start":1288,"enrollment":1329,"conditions":1330,"interventions":1332},"NCT01367613","Open-Label Treatment Extension of Protocol MNTX 302",[87],"2006-01",89,[1331],"Terminal Illness",[1277],{"nctId":1334,"briefTitle":1335,"status":101,"phases":1336,"primaryCompletion":1319,"completion":1319,"start":1320,"enrollment":1337,"conditions":1338,"interventions":1339},"NCT01367600","Open-Label Treatment Extension of Protocol MNTX 301",[87],27,[1331],[1277],{"nctId":1341,"briefTitle":1342,"status":101,"phases":1343,"primaryCompletion":1344,"completion":1344,"start":1345,"enrollment":1346,"conditions":1347,"interventions":1349},"NCT00402038","Study of Methylnaltrexone (MNTX) for the Relief of Constipation",[87],"2005-10","2004-02",134,[1348],"Advance Illness Patients With OIC",[1277,1301],{"trials":1351,"activeCount":95},[],{"trials":1353,"activeCount":95},[],{"intervention":1355,"totalTrials":604,"cells":1356},"IDP-126 Gel",{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1371,"PHASE3":1396,"PHASE4":1415,"NA":1417},{"trials":1358,"activeCount":95},[],{"trials":1360,"activeCount":95},[1361],{"nctId":1362,"briefTitle":1363,"status":101,"phases":1364,"primaryCompletion":1365,"completion":1365,"start":1366,"enrollment":1367,"conditions":1368,"interventions":1369},"NCT03653403","Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel",[85],"2019-06-19","2018-08-08",61,[15],[1355,1370],"Control Gel",{"trials":1372,"activeCount":95},[1373,1384],{"nctId":1374,"briefTitle":1375,"status":101,"phases":1376,"primaryCompletion":1377,"completion":1377,"start":1378,"enrollment":1379,"conditions":1380,"interventions":1381},"NCT04892706","Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel",[86],"2022-09-28","2021-06-11",686,[15],[1355,1382,1383],"IDP-126 Vehicle Gel","Epiduo® Forte Gel",{"nctId":1385,"briefTitle":1386,"status":101,"phases":1387,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":1391,"interventions":1392},"NCT03170388","A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris",[86],"2019-04-23","2017-10-05",741,[15],[1355,1393,1394,1395,1382],"IDP-126 Component A","IDP-126 Component B","IDP-126 Component C",{"trials":1397,"activeCount":95},[1398,1407],{"nctId":1399,"briefTitle":1400,"status":101,"phases":1401,"primaryCompletion":1402,"completion":1402,"start":1403,"enrollment":1404,"conditions":1405,"interventions":1406},"NCT04214639","Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris",[87],"2021-01-18","2020-01-17",183,[15],[1355,1382],{"nctId":1408,"briefTitle":1400,"status":101,"phases":1409,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":1412,"conditions":1413,"interventions":1414},"NCT04214652",[87],"2021-03-18","2020-01-27",180,[15],[1355,1382],{"trials":1416,"activeCount":95},[],{"trials":1418,"activeCount":95},[],{"intervention":658,"totalTrials":604,"cells":1420},{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1439,"PHASE4":1449,"NA":1451},{"trials":1422,"activeCount":95},[],{"trials":1424,"activeCount":95},[],{"trials":1426,"activeCount":95},[1427,1431,1435],{"nctId":651,"briefTitle":652,"status":101,"phases":1428,"primaryCompletion":641,"completion":181,"start":654,"enrollment":655,"conditions":1429,"interventions":1430},[86],[18],[658,659,630,188],{"nctId":661,"briefTitle":662,"status":101,"phases":1432,"primaryCompletion":664,"completion":641,"start":665,"enrollment":666,"conditions":1433,"interventions":1434},[86],[18],[630,647,658,659],{"nctId":670,"briefTitle":671,"status":101,"phases":1436,"primaryCompletion":113,"completion":113,"start":673,"enrollment":6,"conditions":1437,"interventions":1438},[86],[25],[630,676,677,658],{"trials":1440,"activeCount":95},[1441,1445],{"nctId":691,"briefTitle":692,"status":101,"phases":1442,"primaryCompletion":694,"completion":695,"start":686,"enrollment":696,"conditions":1443,"interventions":1444},[87],[25],[630,658],{"nctId":700,"briefTitle":692,"status":101,"phases":1446,"primaryCompletion":702,"completion":703,"start":704,"enrollment":705,"conditions":1447,"interventions":1448},[87],[25],[630,658],{"trials":1450,"activeCount":95},[],{"trials":1452,"activeCount":95},[],{"intervention":1454,"totalTrials":604,"cells":1455},"210 mg brodalumab",{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1460,"PHASE3":1462,"PHASE4":1510,"NA":1512},{"trials":1457,"activeCount":95},[],{"trials":1459,"activeCount":95},[],{"trials":1461,"activeCount":95},[],{"trials":1463,"activeCount":95},[1464,1475,1485,1494,1501],{"nctId":1465,"briefTitle":1466,"status":101,"phases":1467,"primaryCompletion":1468,"completion":1468,"start":1469,"enrollment":1470,"conditions":1471,"interventions":1473},"NCT02024646","Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis",[87],"2015-10","2014-03",484,[1472],"Psoriatic Arthritis",[1454,1474],"140 mg brodalumab",{"nctId":1476,"briefTitle":1477,"status":600,"phases":1478,"primaryCompletion":114,"completion":1468,"start":1479,"enrollment":1480,"conditions":1481,"interventions":1483},"NCT01708603","P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis",[87],"2012-08",1831,[1482],"Moderate to Severe Plaque Psoriasis",[1454,1474,1484],"ustekinumab",{"nctId":1486,"briefTitle":1487,"status":600,"phases":1488,"primaryCompletion":1489,"completion":1468,"start":1490,"enrollment":1491,"conditions":1492,"interventions":1493},"NCT01708629","Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects",[87],"2014-08","2012-09",1881,[25],[1454,1474,1484],{"nctId":1495,"briefTitle":1496,"status":600,"phases":1497,"primaryCompletion":1468,"completion":1468,"start":1469,"enrollment":1498,"conditions":1499,"interventions":1500},"NCT02029495","Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis",[87],478,[1472],[1454,1474],{"nctId":1502,"briefTitle":1503,"status":600,"phases":1504,"primaryCompletion":1505,"completion":1506,"start":1479,"enrollment":1507,"conditions":1508,"interventions":1509},"NCT01708590","Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects",[87],"2014-05","2015-08",661,[18],[1454,1474],{"trials":1511,"activeCount":95},[],{"trials":1513,"activeCount":95},[],{"intervention":1474,"totalTrials":604,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1544,"NA":1546},{"trials":1517,"activeCount":95},[],{"trials":1519,"activeCount":95},[],{"trials":1521,"activeCount":95},[],{"trials":1523,"activeCount":95},[1524,1528,1532,1536,1540],{"nctId":1465,"briefTitle":1466,"status":101,"phases":1525,"primaryCompletion":1468,"completion":1468,"start":1469,"enrollment":1470,"conditions":1526,"interventions":1527},[87],[1472],[1454,1474],{"nctId":1476,"briefTitle":1477,"status":600,"phases":1529,"primaryCompletion":114,"completion":1468,"start":1479,"enrollment":1480,"conditions":1530,"interventions":1531},[87],[1482],[1454,1474,1484],{"nctId":1486,"briefTitle":1487,"status":600,"phases":1533,"primaryCompletion":1489,"completion":1468,"start":1490,"enrollment":1491,"conditions":1534,"interventions":1535},[87],[25],[1454,1474,1484],{"nctId":1495,"briefTitle":1496,"status":600,"phases":1537,"primaryCompletion":1468,"completion":1468,"start":1469,"enrollment":1498,"conditions":1538,"interventions":1539},[87],[1472],[1454,1474],{"nctId":1502,"briefTitle":1503,"status":600,"phases":1541,"primaryCompletion":1505,"completion":1506,"start":1479,"enrollment":1507,"conditions":1542,"interventions":1543},[87],[18],[1454,1474],{"trials":1545,"activeCount":95},[],{"trials":1547,"activeCount":95},[],{"intervention":1382,"totalTrials":168,"cells":1549},{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1564,"PHASE4":1574,"NA":1576},{"trials":1551,"activeCount":95},[],{"trials":1553,"activeCount":95},[],{"trials":1555,"activeCount":95},[1556,1560],{"nctId":1374,"briefTitle":1375,"status":101,"phases":1557,"primaryCompletion":1377,"completion":1377,"start":1378,"enrollment":1379,"conditions":1558,"interventions":1559},[86],[15],[1355,1382,1383],{"nctId":1385,"briefTitle":1386,"status":101,"phases":1561,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":1562,"interventions":1563},[86],[15],[1355,1393,1394,1395,1382],{"trials":1565,"activeCount":95},[1566,1570],{"nctId":1399,"briefTitle":1400,"status":101,"phases":1567,"primaryCompletion":1402,"completion":1402,"start":1403,"enrollment":1404,"conditions":1568,"interventions":1569},[87],[15],[1355,1382],{"nctId":1408,"briefTitle":1400,"status":101,"phases":1571,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":1412,"conditions":1572,"interventions":1573},[87],[15],[1355,1382],{"trials":1575,"activeCount":95},[],{"trials":1577,"activeCount":95},[],{"intervention":892,"totalTrials":168,"cells":1579},{"EARLY_PHASE1":1580,"PHASE1":1582,"PHASE2":1590,"PHASE3":1596,"PHASE4":1617,"NA":1619},{"trials":1581,"activeCount":95},[],{"trials":1583,"activeCount":95},[1584],{"nctId":1585,"briefTitle":1586,"status":101,"phases":1587,"primaryCompletion":641,"completion":181,"start":182,"enrollment":1232,"conditions":1588,"interventions":1589},"NCT02849873","Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream",[85],[30],[892,647],{"trials":1591,"activeCount":95},[1592],{"nctId":884,"briefTitle":885,"status":101,"phases":1593,"primaryCompletion":887,"completion":888,"start":889,"enrollment":592,"conditions":1594,"interventions":1595},[86],[15],[892,647,893,861],{"trials":1597,"activeCount":95},[1598,1608],{"nctId":1599,"briefTitle":1600,"status":101,"phases":1601,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":1604,"conditions":1605,"interventions":1606},"NCT03168334","A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)",[87],"2018-07-24","2017-07-11",801,[15],[892,1607],"IDP-123 Vehicle Lotion",{"nctId":1609,"briefTitle":1610,"status":101,"phases":1611,"primaryCompletion":1612,"completion":1612,"start":1613,"enrollment":1614,"conditions":1615,"interventions":1616},"NCT03168321","A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)",[87],"2018-06-07","2017-06-29",813,[15],[892,1607],{"trials":1618,"activeCount":95},[],{"trials":1620,"activeCount":95},[],{"intervention":1622,"totalTrials":168,"cells":1623},"IDP-120 Gel",{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1636,"PHASE3":1650,"PHASE4":1671,"NA":1673},{"trials":1625,"activeCount":95},[],{"trials":1627,"activeCount":95},[1628],{"nctId":1629,"briefTitle":1630,"status":101,"phases":1631,"primaryCompletion":1632,"completion":1633,"start":182,"enrollment":733,"conditions":1634,"interventions":1635},"NCT02850003","Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel",[85],"2016-10","2016-11",[30],[1622],{"trials":1637,"activeCount":95},[1638],{"nctId":1639,"briefTitle":1640,"status":101,"phases":1641,"primaryCompletion":1642,"completion":1643,"start":889,"enrollment":1644,"conditions":1645,"interventions":1646},"NCT03003247","Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris",[86],"2016-08-31","2016-09-30",364,[15],[1622,1647,1648,1649],"IDP 120 Component A Gel","IDP 120 Component B Gel","IDP 120 Vehicle Gel",{"trials":1651,"activeCount":95},[1652,1662],{"nctId":1653,"briefTitle":1654,"status":101,"phases":1655,"primaryCompletion":1656,"completion":1656,"start":1657,"enrollment":1658,"conditions":1659,"interventions":1660},"NCT03664752","Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris",[87],"2020-05-07","2018-12-10",585,[15],[1622,1661],"IDP-120 Vehicle Gel",{"nctId":1663,"briefTitle":1654,"status":101,"phases":1664,"primaryCompletion":1665,"completion":1665,"start":1666,"enrollment":1667,"conditions":1668,"interventions":1669},"NCT03664739",[87],"2020-03-23","2018-12-05",608,[15],[1622,1670],"IDp-120 Vehicle Gel",{"trials":1672,"activeCount":95},[],{"trials":1674,"activeCount":95},[],{"intervention":1301,"totalTrials":1676,"cells":1677},3,{"EARLY_PHASE1":1678,"PHASE1":1680,"PHASE2":1686,"PHASE3":1688,"PHASE4":1698,"NA":1700},{"trials":1679,"activeCount":95},[],{"trials":1681,"activeCount":95},[1682],{"nctId":1293,"briefTitle":1294,"status":101,"phases":1683,"primaryCompletion":1224,"completion":1224,"start":1231,"enrollment":338,"conditions":1684,"interventions":1685},[85],[1297],[1277,1299,1300,1301],{"trials":1687,"activeCount":95},[],{"trials":1689,"activeCount":95},[1690,1694],{"nctId":1316,"briefTitle":1317,"status":101,"phases":1691,"primaryCompletion":1319,"completion":1319,"start":1320,"enrollment":655,"conditions":1692,"interventions":1693},[87],[1322],[1277,1301,1277],{"nctId":1341,"briefTitle":1342,"status":101,"phases":1695,"primaryCompletion":1344,"completion":1344,"start":1345,"enrollment":1346,"conditions":1696,"interventions":1697},[87],[1348],[1277,1301],{"trials":1699,"activeCount":95},[],{"trials":1701,"activeCount":95},[],{"intervention":1703,"totalTrials":1676,"cells":1704},"N-methylnaltrexone bromide",{"EARLY_PHASE1":1705,"PHASE1":1707,"PHASE2":1709,"PHASE3":1718,"PHASE4":1736,"NA":1738},{"trials":1706,"activeCount":95},[],{"trials":1708,"activeCount":95},[],{"trials":1710,"activeCount":95},[1711],{"nctId":1712,"briefTitle":1713,"status":101,"phases":1714,"primaryCompletion":800,"completion":800,"start":1210,"enrollment":1715,"conditions":1716,"interventions":1717},"NCT00547586","Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain",[86],122,[22],[1703],{"trials":1719,"activeCount":95},[1720,1727],{"nctId":1721,"briefTitle":1722,"status":101,"phases":1723,"primaryCompletion":545,"completion":545,"start":524,"enrollment":1724,"conditions":1725,"interventions":1726},"NCT00529087","Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain",[87],460,[22],[1703],{"nctId":1728,"briefTitle":1729,"status":101,"phases":1730,"primaryCompletion":1731,"completion":1731,"start":1732,"enrollment":1733,"conditions":1734,"interventions":1735},"NCT00804141","Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation",[87],"2010-09-20","2008-12-03",1040,[22],[1703],{"trials":1737,"activeCount":95},[],{"trials":1739,"activeCount":95},[],{"intervention":1741,"totalTrials":1676,"cells":1742},"crofelemer",{"EARLY_PHASE1":1743,"PHASE1":1745,"PHASE2":1747,"PHASE3":1767,"PHASE4":1781,"NA":1783},{"trials":1744,"activeCount":95},[],{"trials":1746,"activeCount":95},[],{"trials":1748,"activeCount":95},[1749,1760],{"nctId":1750,"briefTitle":1751,"status":101,"phases":1752,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1755,"conditions":1756,"interventions":1759},"NCT00101725","A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome",[86],"2005-11","2004-12",245,[528,1757,340,1758],"Colonic Diseases","Gastrointestinal Disease",[1741],{"nctId":1761,"briefTitle":1762,"status":101,"phases":1763,"primaryCompletion":1186,"completion":1186,"start":1177,"enrollment":1764,"conditions":1765,"interventions":1766},"NCT00461526","Diarrhea Predominant Irritable Bowel Syndrome in Females",[86],240,[528],[1741],{"trials":1768,"activeCount":95},[1769],{"nctId":1770,"briefTitle":1771,"status":101,"phases":1772,"primaryCompletion":1773,"completion":1773,"start":1774,"enrollment":1775,"conditions":1776,"interventions":1779},"NCT01374490","Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea",[87],"2012-10-31","2011-06-07",250,[1777,1778],"HIV Enteropathy","Diarrhea With HIV",[1780],"Crofelemer",{"trials":1782,"activeCount":95},[],{"trials":1784,"activeCount":95},[],{"intervention":1786,"totalTrials":1676,"cells":1787},"Budesonide",{"EARLY_PHASE1":1788,"PHASE1":1790,"PHASE2":1792,"PHASE3":1794,"PHASE4":1823,"NA":1825},{"trials":1789,"activeCount":95},[],{"trials":1791,"activeCount":95},[],{"trials":1793,"activeCount":95},[],{"trials":1795,"activeCount":95},[1796,1807,1815],{"nctId":1797,"briefTitle":1798,"status":101,"phases":1799,"primaryCompletion":1800,"completion":1800,"start":1801,"enrollment":1802,"conditions":1803,"interventions":1806},"NCT01008423","Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis",[87],"2013-03-18","2009-11-20",281,[1804,1805],"Proctitis","Proctosigmoiditis",[1786],{"nctId":1808,"briefTitle":1809,"status":101,"phases":1810,"primaryCompletion":732,"completion":731,"start":1811,"enrollment":1367,"conditions":1812,"interventions":1814},"NCT01100112","(CB-01-02\u002F06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets",[87],"2010-02",[1813],"Colitis, Ulcerative",[1786],{"nctId":1816,"briefTitle":1798,"status":101,"phases":1817,"primaryCompletion":1818,"completion":1818,"start":1819,"enrollment":1820,"conditions":1821,"interventions":1822},"NCT01008410",[87],"2013-04-29","2009-11-17",265,[1804,1805],[1786],{"trials":1824,"activeCount":95},[],{"trials":1826,"activeCount":95},[],{"intervention":186,"totalTrials":1676,"cells":1828},{"EARLY_PHASE1":1829,"PHASE1":1831,"PHASE2":1833,"PHASE3":1839,"PHASE4":1849,"NA":1851},{"trials":1830,"activeCount":95},[],{"trials":1832,"activeCount":95},[],{"trials":1834,"activeCount":95},[1835],{"nctId":177,"briefTitle":178,"status":101,"phases":1836,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":1837,"interventions":1838},[86],[18],[186,187,53,188],{"trials":1840,"activeCount":95},[1841,1845],{"nctId":192,"briefTitle":193,"status":101,"phases":1842,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":1843,"interventions":1844},[87],[25],[53,186],{"nctId":201,"briefTitle":193,"status":101,"phases":1846,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":1847,"interventions":1848},[87],[25],[53,186],{"trials":1850,"activeCount":95},[],{"trials":1852,"activeCount":95},[],{"intervention":1854,"totalTrials":1676,"cells":1855},"Viramidine",{"EARLY_PHASE1":1856,"PHASE1":1858,"PHASE2":1860,"PHASE3":1870,"PHASE4":1892,"NA":1894},{"trials":1857,"activeCount":95},[],{"trials":1859,"activeCount":95},[],{"trials":1861,"activeCount":95},[1862],{"nctId":1863,"briefTitle":1864,"status":600,"phases":1865,"completion":1202,"start":1753,"enrollment":279,"conditions":1866,"interventions":1868},"NCT00305383","Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C",[86],[1867],"Hepatitis C, Chronic",[1854,1869],"Peginterferon alfa-2b",{"trials":1871,"activeCount":95},[1872,1884],{"nctId":1873,"briefTitle":1874,"status":101,"phases":1875,"primaryCompletion":1876,"completion":1876,"start":1877,"enrollment":1878,"conditions":1879,"interventions":1881},"NCT00093093","Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive",[87],"2006-05","2004-06",900,[1880],"Chronic Hepatitis C",[1854,1882,1883],"Ribavirin","pegylated interferon alfa-2a",{"nctId":1885,"briefTitle":1886,"status":101,"phases":1887,"primaryCompletion":1328,"completion":1328,"start":1888,"enrollment":1878,"conditions":1889,"interventions":1890},"NCT00230958","Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive",[87],"2003-12",[1880],[1854,1882,1891],"pegylated interferon alfa-2b",{"trials":1893,"activeCount":95},[],{"trials":1895,"activeCount":95},[],{"intervention":1882,"totalTrials":1676,"cells":1897},{"EARLY_PHASE1":1898,"PHASE1":1900,"PHASE2":1902,"PHASE3":1912,"PHASE4":1922,"NA":1924},{"trials":1899,"activeCount":95},[],{"trials":1901,"activeCount":95},[],{"trials":1903,"activeCount":95},[1904],{"nctId":1905,"briefTitle":1906,"status":101,"phases":1907,"primaryCompletion":1027,"completion":831,"start":1203,"enrollment":1908,"conditions":1909,"interventions":1910},"NCT00446134","Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)",[86],278,[1880],[1911,1911,1911,1882],"Taribavirin",{"trials":1913,"activeCount":95},[1914,1918],{"nctId":1873,"briefTitle":1874,"status":101,"phases":1915,"primaryCompletion":1876,"completion":1876,"start":1877,"enrollment":1878,"conditions":1916,"interventions":1917},[87],[1880],[1854,1882,1883],{"nctId":1885,"briefTitle":1886,"status":101,"phases":1919,"primaryCompletion":1328,"completion":1328,"start":1888,"enrollment":1878,"conditions":1920,"interventions":1921},[87],[1880],[1854,1882,1891],{"trials":1923,"activeCount":95},[],{"trials":1925,"activeCount":95},[],{"intervention":1927,"totalTrials":1676,"cells":1928},"Tramadol HCl ER",{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1935,"PHASE4":1962,"NA":1964},{"trials":1930,"activeCount":95},[],{"trials":1932,"activeCount":95},[],{"trials":1934,"activeCount":95},[],{"trials":1936,"activeCount":95},[1937,1947,1955],{"nctId":1938,"briefTitle":1939,"status":101,"phases":1940,"completion":1941,"start":1942,"enrollment":1943,"conditions":1944,"interventions":1946},"NCT00347724","A Study Comparing the Effectiveness and Safety of Extended-release Tramadol Versus Placebo in the Treatment of Chronic Low Back Pain",[87],"2001-11","2000-11",600,[1945],"Chronic Pain",[1927],{"nctId":1948,"briefTitle":1949,"status":101,"phases":1950,"completion":1888,"start":1951,"enrollment":1952,"conditions":1953,"interventions":1954},"NCT00325858","A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and\u002For Hip",[87],"2002-01",1000,[1945],[1927],{"nctId":1956,"briefTitle":1957,"status":101,"phases":1958,"completion":1959,"start":1942,"enrollment":1755,"conditions":1960,"interventions":1961},"NCT00348010","A Study Comparing the Effectiveness and Safety of Extended Release Tramadol Versus Placebo for the Treatment of Osteoarthritis (OA) of the Knee",[87],"2001-07",[1945],[1927],{"trials":1963,"activeCount":95},[],{"trials":1965,"activeCount":95},[],{"intervention":1967,"totalTrials":132,"cells":1968},"IDP-121 Vehicle Lotion",{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1975,"PHASE4":1995,"NA":1997},{"trials":1970,"activeCount":95},[],{"trials":1972,"activeCount":95},[],{"trials":1974,"activeCount":95},[],{"trials":1976,"activeCount":95},[1977,1987],{"nctId":1978,"briefTitle":1979,"status":101,"phases":1980,"primaryCompletion":1981,"completion":1981,"start":1982,"enrollment":1983,"conditions":1984,"interventions":1985},"NCT02965456","Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris",[87],"2017-02-23","2015-11-04",820,[30],[1986,1967],"IDP 121 Lotion",{"nctId":1988,"briefTitle":1979,"status":101,"phases":1989,"primaryCompletion":1990,"completion":1990,"start":1991,"enrollment":1983,"conditions":1992,"interventions":1993},"NCT02932306",[87],"2017-02-22","2015-11-03",[30],[1994,1967],"IDP-121 Lotion",{"trials":1996,"activeCount":95},[],{"trials":1998,"activeCount":95},[],{"intervention":2000,"totalTrials":132,"cells":2001},"Rifaximin EIR",{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2006,"PHASE3":2008,"PHASE4":2029,"NA":2031},{"trials":2003,"activeCount":95},[],{"trials":2005,"activeCount":95},[],{"trials":2007,"activeCount":95},[],{"trials":2009,"activeCount":95},[2010,2020],{"nctId":2011,"briefTitle":2012,"status":600,"phases":2013,"primaryCompletion":2014,"completion":2014,"start":2015,"enrollment":2016,"conditions":2017,"interventions":2019},"NCT02240108","One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease",[87],"2017-10-06","2014-10-28",81,[2018],"Crohn's Disease",[2000],{"nctId":2021,"briefTitle":2022,"status":600,"phases":2023,"primaryCompletion":2024,"completion":2024,"start":2025,"enrollment":2026,"conditions":2027,"interventions":2028},"NCT02240121","One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease",[87],"2017-08-16","2014-08-21",80,[2018],[2000],{"trials":2030,"activeCount":95},[],{"trials":2032,"activeCount":95},[],{"intervention":1994,"totalTrials":132,"cells":2034},{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2045,"PHASE3":2047,"PHASE4":2053,"NA":2055},{"trials":2036,"activeCount":95},[],{"trials":2038,"activeCount":95},[2039],{"nctId":2040,"briefTitle":2041,"status":101,"phases":2042,"primaryCompletion":888,"completion":1632,"start":673,"enrollment":733,"conditions":2043,"interventions":2044},"NCT02849860","Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris",[85],[30],[1994],{"trials":2046,"activeCount":95},[],{"trials":2048,"activeCount":95},[2049],{"nctId":1988,"briefTitle":1979,"status":101,"phases":2050,"primaryCompletion":1990,"completion":1990,"start":1991,"enrollment":1983,"conditions":2051,"interventions":2052},[87],[30],[1994,1967],{"trials":2054,"activeCount":95},[],{"trials":2056,"activeCount":95},[],{"intervention":2058,"totalTrials":132,"cells":2059},"Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks",{"EARLY_PHASE1":2060,"PHASE1":2062,"PHASE2":2064,"PHASE3":2066,"PHASE4":2081,"NA":2083},{"trials":2061,"activeCount":95},[],{"trials":2063,"activeCount":95},[],{"trials":2065,"activeCount":95},[],{"trials":2067,"activeCount":95},[2068,2075],{"nctId":2069,"briefTitle":2070,"status":101,"phases":2071,"completion":1028,"start":1877,"enrollment":2072,"conditions":2073,"interventions":2074},"NCT00086541","Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy",[87],515,[1880],[2058],{"nctId":2076,"briefTitle":2070,"status":101,"phases":2077,"primaryCompletion":1169,"completion":1169,"start":1319,"enrollment":2078,"conditions":2079,"interventions":2080},"NCT00162734",[87],144,[1880],[2058],{"trials":2082,"activeCount":95},[],{"trials":2084,"activeCount":95},[],{"intervention":2086,"totalTrials":132,"cells":2087},"IDP-124 Lotion",{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2094,"PHASE4":2114,"NA":2116},{"trials":2089,"activeCount":95},[],{"trials":2091,"activeCount":95},[],{"trials":2093,"activeCount":95},[],{"trials":2095,"activeCount":95},[2096,2105],{"nctId":2097,"briefTitle":2098,"status":101,"phases":2099,"primaryCompletion":2100,"completion":2100,"start":1602,"enrollment":2101,"conditions":2102,"interventions":2103},"NCT03002571","Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)",[87],"2020-04-14",338,[460],[2086,2104],"IDP-124 Vehicle Lotion",{"nctId":2106,"briefTitle":2107,"status":101,"phases":2108,"primaryCompletion":2109,"completion":2109,"start":2110,"enrollment":2111,"conditions":2112,"interventions":2113},"NCT03058783","Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects",[87],"2020-05-12","2018-08-14",328,[460],[2086,2104],{"trials":2115,"activeCount":95},[],{"trials":2117,"activeCount":95},[],{"intervention":2104,"totalTrials":132,"cells":2119},{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2126,"PHASE4":2136,"NA":2138},{"trials":2121,"activeCount":95},[],{"trials":2123,"activeCount":95},[],{"trials":2125,"activeCount":95},[],{"trials":2127,"activeCount":95},[2128,2132],{"nctId":2097,"briefTitle":2098,"status":101,"phases":2129,"primaryCompletion":2100,"completion":2100,"start":1602,"enrollment":2101,"conditions":2130,"interventions":2131},[87],[460],[2086,2104],{"nctId":2106,"briefTitle":2107,"status":101,"phases":2133,"primaryCompletion":2109,"completion":2109,"start":2110,"enrollment":2111,"conditions":2134,"interventions":2135},[87],[460],[2086,2104],{"trials":2137,"activeCount":95},[],{"trials":2139,"activeCount":95},[],{"intervention":2141,"totalTrials":132,"cells":2142},"Balsalazide disodium",{"EARLY_PHASE1":2143,"PHASE1":2145,"PHASE2":2147,"PHASE3":2149,"PHASE4":2168,"NA":2170},{"trials":2144,"activeCount":95},[],{"trials":2146,"activeCount":95},[],{"trials":2148,"activeCount":95},[],{"trials":2150,"activeCount":95},[2151,2160],{"nctId":2152,"briefTitle":2153,"status":101,"phases":2154,"primaryCompletion":1187,"completion":2155,"start":1876,"enrollment":2156,"conditions":2157,"interventions":2159},"NCT00408174","Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis",[87],"2007-11",400,[2158,20],"Inflammatory Bowel Disease",[2141],{"nctId":2161,"briefTitle":2162,"status":101,"phases":2163,"primaryCompletion":1027,"completion":545,"start":1177,"enrollment":2164,"conditions":2165,"interventions":2166},"NCT00486031","Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study",[87],443,[2158,20],[2167],"Balsalazide Disodium",{"trials":2169,"activeCount":95},[],{"trials":2171,"activeCount":95},[],{"intervention":1607,"totalTrials":132,"cells":2173},{"EARLY_PHASE1":2174,"PHASE1":2176,"PHASE2":2178,"PHASE3":2180,"PHASE4":2190,"NA":2192},{"trials":2175,"activeCount":95},[],{"trials":2177,"activeCount":95},[],{"trials":2179,"activeCount":95},[],{"trials":2181,"activeCount":95},[2182,2186],{"nctId":1599,"briefTitle":1600,"status":101,"phases":2183,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":1604,"conditions":2184,"interventions":2185},[87],[15],[892,1607],{"nctId":1609,"briefTitle":1610,"status":101,"phases":2187,"primaryCompletion":1612,"completion":1612,"start":1613,"enrollment":1614,"conditions":2188,"interventions":2189},[87],[15],[892,1607],{"trials":2191,"activeCount":95},[],{"trials":2193,"activeCount":95},[],{"intervention":2195,"totalTrials":132,"cells":2196},"Granulated mesalamine",{"EARLY_PHASE1":2197,"PHASE1":2199,"PHASE2":2201,"PHASE3":2203,"PHASE4":2219,"NA":2221},{"trials":2198,"activeCount":95},[],{"trials":2200,"activeCount":95},[],{"trials":2202,"activeCount":95},[],{"trials":2204,"activeCount":95},[2205,2212],{"nctId":2206,"briefTitle":2207,"status":101,"phases":2208,"primaryCompletion":524,"completion":1210,"start":1754,"enrollment":2209,"conditions":2210,"interventions":2211},"NCT00767728","Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis",[87],256,[20],[2195],{"nctId":2213,"briefTitle":2214,"status":101,"phases":2215,"primaryCompletion":1202,"completion":1210,"start":1754,"enrollment":2216,"conditions":2217,"interventions":2218},"NCT00744016","Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis",[87],305,[20],[2195],{"trials":2220,"activeCount":95},[],{"trials":2222,"activeCount":95},[],{"intervention":1661,"totalTrials":132,"cells":2224},{"EARLY_PHASE1":2225,"PHASE1":2227,"PHASE2":2229,"PHASE3":2231,"PHASE4":2241,"NA":2243},{"trials":2226,"activeCount":95},[],{"trials":2228,"activeCount":95},[],{"trials":2230,"activeCount":95},[],{"trials":2232,"activeCount":95},[2233,2237],{"nctId":1653,"briefTitle":1654,"status":101,"phases":2234,"primaryCompletion":1656,"completion":1656,"start":1657,"enrollment":1658,"conditions":2235,"interventions":2236},[87],[15],[1622,1661],{"nctId":1663,"briefTitle":1654,"status":101,"phases":2238,"primaryCompletion":1665,"completion":1665,"start":1666,"enrollment":1667,"conditions":2239,"interventions":2240},[87],[15],[1622,1670],{"trials":2242,"activeCount":95},[],{"trials":2244,"activeCount":95},[],{"intervention":1484,"totalTrials":132,"cells":2246},{"EARLY_PHASE1":2247,"PHASE1":2249,"PHASE2":2251,"PHASE3":2253,"PHASE4":2263,"NA":2265},{"trials":2248,"activeCount":95},[],{"trials":2250,"activeCount":95},[],{"trials":2252,"activeCount":95},[],{"trials":2254,"activeCount":95},[2255,2259],{"nctId":1476,"briefTitle":1477,"status":600,"phases":2256,"primaryCompletion":114,"completion":1468,"start":1479,"enrollment":1480,"conditions":2257,"interventions":2258},[87],[1482],[1454,1474,1484],{"nctId":1486,"briefTitle":1487,"status":600,"phases":2260,"primaryCompletion":1489,"completion":1468,"start":1490,"enrollment":1491,"conditions":2261,"interventions":2262},[87],[25],[1454,1474,1484],{"trials":2264,"activeCount":95},[],{"trials":2266,"activeCount":95},[],{"intervention":2268,"totalTrials":135,"cells":2269},"Neuromultivit",{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2274,"PHASE3":2276,"PHASE4":2289,"NA":2291},{"trials":2271,"activeCount":95},[],{"trials":2273,"activeCount":95},[],{"trials":2275,"activeCount":95},[],{"trials":2277,"activeCount":95},[2278],{"nctId":2279,"briefTitle":2280,"status":101,"phases":2281,"primaryCompletion":2282,"completion":889,"start":2283,"enrollment":279,"conditions":2284,"interventions":2286},"NCT02508805","Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy",[87],"2015-09","2015-05",[2285],"Vertebrogenic Radiculopathy L5, S1",[2268,2287,2288],"Voltaren","Sirdalud",{"trials":2290,"activeCount":95},[],{"trials":2292,"activeCount":95},[],{"intervention":2287,"totalTrials":135,"cells":2294},{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2299,"PHASE3":2301,"PHASE4":2307,"NA":2309},{"trials":2296,"activeCount":95},[],{"trials":2298,"activeCount":95},[],{"trials":2300,"activeCount":95},[],{"trials":2302,"activeCount":95},[2303],{"nctId":2279,"briefTitle":2280,"status":101,"phases":2304,"primaryCompletion":2282,"completion":889,"start":2283,"enrollment":279,"conditions":2305,"interventions":2306},[87],[2285],[2268,2287,2288],{"trials":2308,"activeCount":95},[],{"trials":2310,"activeCount":95},[],{"intervention":2288,"totalTrials":135,"cells":2312},{"EARLY_PHASE1":2313,"PHASE1":2315,"PHASE2":2317,"PHASE3":2319,"PHASE4":2325,"NA":2327},{"trials":2314,"activeCount":95},[],{"trials":2316,"activeCount":95},[],{"trials":2318,"activeCount":95},[],{"trials":2320,"activeCount":95},[2321],{"nctId":2279,"briefTitle":2280,"status":101,"phases":2322,"primaryCompletion":2282,"completion":889,"start":2283,"enrollment":279,"conditions":2323,"interventions":2324},[87],[2285],[2268,2287,2288],{"trials":2326,"activeCount":95},[],{"trials":2328,"activeCount":95},[],{"intervention":1986,"totalTrials":135,"cells":2330},{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2335,"PHASE3":2337,"PHASE4":2343,"NA":2345},{"trials":2332,"activeCount":95},[],{"trials":2334,"activeCount":95},[],{"trials":2336,"activeCount":95},[],{"trials":2338,"activeCount":95},[2339],{"nctId":1978,"briefTitle":1979,"status":101,"phases":2340,"primaryCompletion":1981,"completion":1981,"start":1982,"enrollment":1983,"conditions":2341,"interventions":2342},[87],[30],[1986,1967],{"trials":2344,"activeCount":95},[],{"trials":2346,"activeCount":95},[],{"intervention":2348,"totalTrials":135,"cells":2349},"Encapsulated Mesalamine Granules",{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2354,"PHASE3":2356,"PHASE4":2367,"NA":2369},{"trials":2351,"activeCount":95},[],{"trials":2353,"activeCount":95},[],{"trials":2355,"activeCount":95},[],{"trials":2357,"activeCount":95},[2358],{"nctId":2359,"briefTitle":2360,"status":101,"phases":2361,"primaryCompletion":2362,"completion":2362,"start":2363,"enrollment":2364,"conditions":2365,"interventions":2366},"NCT00326209","Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission",[87],"2008-05-05","2005-12-22",393,[20],[2348],{"trials":2368,"activeCount":95},[],{"trials":2370,"activeCount":95},[],{"intervention":2372,"totalTrials":135,"cells":2373},"Tramadol Hydrochloride",{"EARLY_PHASE1":2374,"PHASE1":2376,"PHASE2":2378,"PHASE3":2380,"PHASE4":2391,"NA":2393},{"trials":2375,"activeCount":95},[],{"trials":2377,"activeCount":95},[],{"trials":2379,"activeCount":95},[],{"trials":2381,"activeCount":95},[2382],{"nctId":2383,"briefTitle":2384,"status":600,"phases":2385,"primaryCompletion":2386,"completion":2386,"start":1052,"enrollment":2387,"conditions":2388,"interventions":2390},"NCT00983736","Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation",[87],"2010-09",1050,[2389],"Premature Ejaculation",[2372],{"trials":2392,"activeCount":95},[],{"trials":2394,"activeCount":95},[],{"intervention":2396,"totalTrials":135,"cells":2397},"Budesonide MMX® 6 mg",{"EARLY_PHASE1":2398,"PHASE1":2400,"PHASE2":2402,"PHASE3":2404,"PHASE4":2417,"NA":2419},{"trials":2399,"activeCount":95},[],{"trials":2401,"activeCount":95},[],{"trials":2403,"activeCount":95},[],{"trials":2405,"activeCount":95},[2406],{"nctId":2407,"briefTitle":2408,"status":101,"phases":2409,"primaryCompletion":1811,"completion":2410,"start":2411,"enrollment":2412,"conditions":2413,"interventions":2414},"NCT00679380","(CB-01-02\u002F02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis",[87],"2010-04","2008-06",514,[20],[2396,2415,2416],"Budesonide MMX® 9 mg","Entocort EC® 3 mg",{"trials":2418,"activeCount":95},[],{"trials":2420,"activeCount":95},[],{"intervention":2415,"totalTrials":135,"cells":2422},{"EARLY_PHASE1":2423,"PHASE1":2425,"PHASE2":2427,"PHASE3":2429,"PHASE4":2435,"NA":2437},{"trials":2424,"activeCount":95},[],{"trials":2426,"activeCount":95},[],{"trials":2428,"activeCount":95},[],{"trials":2430,"activeCount":95},[2431],{"nctId":2407,"briefTitle":2408,"status":101,"phases":2432,"primaryCompletion":1811,"completion":2410,"start":2411,"enrollment":2412,"conditions":2433,"interventions":2434},[87],[20],[2396,2415,2416],{"trials":2436,"activeCount":95},[],{"trials":2438,"activeCount":95},[],{"intervention":2416,"totalTrials":135,"cells":2440},{"EARLY_PHASE1":2441,"PHASE1":2443,"PHASE2":2445,"PHASE3":2447,"PHASE4":2453,"NA":2455},{"trials":2442,"activeCount":95},[],{"trials":2444,"activeCount":95},[],{"trials":2446,"activeCount":95},[],{"trials":2448,"activeCount":95},[2449],{"nctId":2407,"briefTitle":2408,"status":101,"phases":2450,"primaryCompletion":1811,"completion":2410,"start":2411,"enrollment":2412,"conditions":2451,"interventions":2452},[87],[20],[2396,2415,2416],{"trials":2454,"activeCount":95},[],{"trials":2456,"activeCount":95},[],{"intervention":2458,"totalTrials":135,"cells":2459},"ACYC",{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2464,"PHASE3":2466,"PHASE4":2478,"NA":2480},{"trials":2461,"activeCount":95},[],{"trials":2463,"activeCount":95},[],{"trials":2465,"activeCount":95},[],{"trials":2467,"activeCount":95},[2468],{"nctId":2469,"briefTitle":2470,"status":101,"phases":2471,"primaryCompletion":776,"completion":2472,"start":2473,"enrollment":2474,"conditions":2475,"interventions":2476},"NCT01701024","Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne",[87],"2013-07","2012-10",498,[30],[2458,2477],"ACYC vehicle",{"trials":2479,"activeCount":95},[],{"trials":2481,"activeCount":95},[],{"intervention":2477,"totalTrials":135,"cells":2483},{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2488,"PHASE3":2490,"PHASE4":2496,"NA":2498},{"trials":2485,"activeCount":95},[],{"trials":2487,"activeCount":95},[],{"trials":2489,"activeCount":95},[],{"trials":2491,"activeCount":95},[2492],{"nctId":2469,"briefTitle":2470,"status":101,"phases":2493,"primaryCompletion":776,"completion":2472,"start":2473,"enrollment":2474,"conditions":2494,"interventions":2495},[87],[30],[2458,2477],{"trials":2497,"activeCount":95},[],{"trials":2499,"activeCount":95},[],{"intervention":1883,"totalTrials":135,"cells":2501},{"EARLY_PHASE1":2502,"PHASE1":2504,"PHASE2":2506,"PHASE3":2508,"PHASE4":2514,"NA":2516},{"trials":2503,"activeCount":95},[],{"trials":2505,"activeCount":95},[],{"trials":2507,"activeCount":95},[],{"trials":2509,"activeCount":95},[2510],{"nctId":1873,"briefTitle":1874,"status":101,"phases":2511,"primaryCompletion":1876,"completion":1876,"start":1877,"enrollment":1878,"conditions":2512,"interventions":2513},[87],[1880],[1854,1882,1883],{"trials":2515,"activeCount":95},[],{"trials":2517,"activeCount":95},[],{"intervention":550,"totalTrials":135,"cells":2519},{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2526,"PHASE4":2532,"NA":2534},{"trials":2521,"activeCount":95},[],{"trials":2523,"activeCount":95},[],{"trials":2525,"activeCount":95},[],{"trials":2527,"activeCount":95},[2528],{"nctId":542,"briefTitle":543,"status":101,"phases":2529,"primaryCompletion":545,"completion":545,"start":525,"enrollment":546,"conditions":2530,"interventions":2531},[87],[548,340],[499,550],{"trials":2533,"activeCount":95},[],{"trials":2535,"activeCount":95},[],{"intervention":2537,"totalTrials":135,"cells":2538},"Budesonide MMX®",{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2543,"PHASE3":2545,"PHASE4":2557,"NA":2559},{"trials":2540,"activeCount":95},[],{"trials":2542,"activeCount":95},[],{"trials":2544,"activeCount":95},[],{"trials":2546,"activeCount":95},[2547],{"nctId":2548,"briefTitle":2549,"status":101,"phases":2550,"primaryCompletion":2551,"completion":2551,"start":2552,"enrollment":2553,"conditions":2554,"interventions":2555},"NCT01532648","Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)",[87],"2013-10-02","2012-01-27",510,[20],[2537,2556],"5-ASA",{"trials":2558,"activeCount":95},[],{"trials":2560,"activeCount":95},[],{"intervention":2556,"totalTrials":135,"cells":2562},{"EARLY_PHASE1":2563,"PHASE1":2565,"PHASE2":2567,"PHASE3":2569,"PHASE4":2575,"NA":2577},{"trials":2564,"activeCount":95},[],{"trials":2566,"activeCount":95},[],{"trials":2568,"activeCount":95},[],{"trials":2570,"activeCount":95},[2571],{"nctId":2548,"briefTitle":2549,"status":101,"phases":2572,"primaryCompletion":2551,"completion":2551,"start":2552,"enrollment":2553,"conditions":2573,"interventions":2574},[87],[20],[2537,2556],{"trials":2576,"activeCount":95},[],{"trials":2578,"activeCount":95},[],{"intervention":2580,"totalTrials":135,"cells":2581},"open-label rifaximin",{"EARLY_PHASE1":2582,"PHASE1":2584,"PHASE2":2586,"PHASE3":2588,"PHASE4":2602,"NA":2604},{"trials":2583,"activeCount":95},[],{"trials":2585,"activeCount":95},[],{"trials":2587,"activeCount":95},[],{"trials":2589,"activeCount":95},[2590],{"nctId":2591,"briefTitle":2592,"status":101,"phases":2593,"primaryCompletion":2594,"completion":2594,"start":2595,"enrollment":2596,"conditions":2597,"interventions":2599},"NCT01543178","Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study",[87],"2014-06","2012-02",2583,[2598],"Irritable Bowel Syndrome With Diarrhea",[2580,2600,2601],"double-blind placebo","double-blind rifaximin",{"trials":2603,"activeCount":95},[],{"trials":2605,"activeCount":95},[],{"intervention":2600,"totalTrials":135,"cells":2607},{"EARLY_PHASE1":2608,"PHASE1":2610,"PHASE2":2612,"PHASE3":2614,"PHASE4":2620,"NA":2622},{"trials":2609,"activeCount":95},[],{"trials":2611,"activeCount":95},[],{"trials":2613,"activeCount":95},[],{"trials":2615,"activeCount":95},[2616],{"nctId":2591,"briefTitle":2592,"status":101,"phases":2617,"primaryCompletion":2594,"completion":2594,"start":2595,"enrollment":2596,"conditions":2618,"interventions":2619},[87],[2598],[2580,2600,2601],{"trials":2621,"activeCount":95},[],{"trials":2623,"activeCount":95},[],{"intervention":2601,"totalTrials":135,"cells":2625},{"EARLY_PHASE1":2626,"PHASE1":2628,"PHASE2":2630,"PHASE3":2632,"PHASE4":2638,"NA":2640},{"trials":2627,"activeCount":95},[],{"trials":2629,"activeCount":95},[],{"trials":2631,"activeCount":95},[],{"trials":2633,"activeCount":95},[2634],{"nctId":2591,"briefTitle":2592,"status":101,"phases":2635,"primaryCompletion":2594,"completion":2594,"start":2595,"enrollment":2596,"conditions":2636,"interventions":2637},[87],[2598],[2580,2600,2601],{"trials":2639,"activeCount":95},[],{"trials":2641,"activeCount":95},[],{"intervention":2643,"totalTrials":135,"cells":2644},"Bisacodyl",{"EARLY_PHASE1":2645,"PHASE1":2647,"PHASE2":2649,"PHASE3":2651,"PHASE4":2663,"NA":2665},{"trials":2646,"activeCount":95},[],{"trials":2648,"activeCount":95},[],{"trials":2650,"activeCount":95},[],{"trials":2652,"activeCount":95},[2653],{"nctId":2654,"briefTitle":2655,"status":101,"phases":2656,"primaryCompletion":642,"completion":2657,"start":2658,"enrollment":2659,"conditions":2660,"interventions":2661},"NCT01982240","12-Week Study of Plecanatide for CIC (The CIC3 Study)",[87],"2015-06","2013-11",1394,[28],[2662,2643],"Plecanatide",{"trials":2664,"activeCount":95},[],{"trials":2666,"activeCount":95},[],{"intervention":2668,"totalTrials":135,"cells":2669},"Tramadol Hydrochloride & Placebo",{"EARLY_PHASE1":2670,"PHASE1":2672,"PHASE2":2674,"PHASE3":2676,"PHASE4":2684,"NA":2686},{"trials":2671,"activeCount":95},[],{"trials":2673,"activeCount":95},[],{"trials":2675,"activeCount":95},[],{"trials":2677,"activeCount":95},[2678],{"nctId":2679,"briefTitle":2680,"status":600,"phases":2681,"primaryCompletion":2386,"completion":2386,"start":555,"enrollment":2387,"conditions":2682,"interventions":2683},"NCT00983151","Study to Evaluate Efficacy and Safety in Males Subjects With Premature Ejaculation",[87],[2389],[2668],{"trials":2685,"activeCount":95},[],{"trials":2687,"activeCount":95},[],{"intervention":2689,"totalTrials":135,"cells":2690},"Budesonide MMX 6 mg",{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2695,"PHASE3":2697,"PHASE4":2708,"NA":2710},{"trials":2692,"activeCount":95},[],{"trials":2694,"activeCount":95},[],{"trials":2696,"activeCount":95},[],{"trials":2698,"activeCount":95},[2699],{"nctId":2700,"briefTitle":2701,"status":101,"phases":2702,"primaryCompletion":2703,"completion":2704,"start":545,"enrollment":2705,"conditions":2706,"interventions":2707},"NCT00801723","(CB-01-02\u002F04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.",[87],"2011-05","2011-06",123,[20],[2689],{"trials":2709,"activeCount":95},[],{"trials":2711,"activeCount":95},[],{"intervention":2713,"totalTrials":135,"cells":2714},"5 ASA, enemas, suppositories, corticosteroids",{"EARLY_PHASE1":2715,"PHASE1":2717,"PHASE2":2719,"PHASE3":2721,"PHASE4":2730,"NA":2732},{"trials":2716,"activeCount":95},[],{"trials":2718,"activeCount":95},[],{"trials":2720,"activeCount":95},[],{"trials":2722,"activeCount":95},[2723],{"nctId":2724,"briefTitle":2725,"status":101,"phases":2726,"primaryCompletion":1203,"completion":1169,"start":525,"enrollment":2727,"conditions":2728,"interventions":2729},"NCT00269438","New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis",[87],225,[20],[2713],{"trials":2731,"activeCount":95},[],{"trials":2733,"activeCount":95},[],{"intervention":2735,"totalTrials":135,"cells":2736},"Omeprazole sodium bicarbonate immediate release PWD\u002FFS",{"EARLY_PHASE1":2737,"PHASE1":2739,"PHASE2":2741,"PHASE3":2743,"PHASE4":2756,"NA":2758},{"trials":2738,"activeCount":95},[],{"trials":2740,"activeCount":95},[],{"trials":2742,"activeCount":95},[],{"trials":2744,"activeCount":95},[2745],{"nctId":2746,"briefTitle":2747,"status":101,"phases":2748,"completion":2749,"start":2750,"enrollment":2751,"conditions":2752,"interventions":2754},"NCT00045799","Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill",[87],"2003-05","2002-05",354,[2753],"Upper Gastrointestinal Bleeding",[2735,2755],"Cimetidine IV",{"trials":2757,"activeCount":95},[],{"trials":2759,"activeCount":95},[],{"intervention":2755,"totalTrials":135,"cells":2761},{"EARLY_PHASE1":2762,"PHASE1":2764,"PHASE2":2766,"PHASE3":2768,"PHASE4":2774,"NA":2776},{"trials":2763,"activeCount":95},[],{"trials":2765,"activeCount":95},[],{"trials":2767,"activeCount":95},[],{"trials":2769,"activeCount":95},[2770],{"nctId":2746,"briefTitle":2747,"status":101,"phases":2771,"completion":2749,"start":2750,"enrollment":2751,"conditions":2772,"interventions":2773},[87],[2753],[2735,2755],{"trials":2775,"activeCount":95},[],{"trials":2777,"activeCount":95},[],{"intervention":2779,"totalTrials":135,"cells":2780},"tramadol ER",{"EARLY_PHASE1":2781,"PHASE1":2783,"PHASE2":2785,"PHASE3":2787,"PHASE4":2797,"NA":2799},{"trials":2782,"activeCount":95},[],{"trials":2784,"activeCount":95},[],{"trials":2786,"activeCount":95},[],{"trials":2788,"activeCount":95},[2789],{"nctId":2790,"briefTitle":2791,"status":101,"phases":2792,"completion":1320,"start":2793,"enrollment":2794,"conditions":2795,"interventions":2796},"NCT00347685","A One-year, Open-label Study to Assess the Safety and Effectiveness of Extended Release Tramadol HCl in the Treatment of Chronic, Non-malignant Pain.",[87],"2000-10",650,[1945],[2779],{"trials":2798,"activeCount":95},[],{"trials":2800,"activeCount":95},[],{"intervention":2802,"totalTrials":135,"cells":2803},"budesonide-MMX® 6 mg",{"EARLY_PHASE1":2804,"PHASE1":2806,"PHASE2":2808,"PHASE3":2810,"PHASE4":2822,"NA":2824},{"trials":2805,"activeCount":95},[],{"trials":2807,"activeCount":95},[],{"trials":2809,"activeCount":95},[],{"trials":2811,"activeCount":95},[2812],{"nctId":2813,"briefTitle":2814,"status":101,"phases":2815,"primaryCompletion":2816,"completion":2817,"start":2411,"enrollment":2553,"conditions":2818,"interventions":2819},"NCT00679432","(CB-01-02\u002F01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis",[87],"2010-05","2010-06",[20],[2802,2820,2821],"budesonide-MMX® 9 mg","Asacol® 400 mg",{"trials":2823,"activeCount":95},[],{"trials":2825,"activeCount":95},[],{"intervention":2820,"totalTrials":135,"cells":2827},{"EARLY_PHASE1":2828,"PHASE1":2830,"PHASE2":2832,"PHASE3":2834,"PHASE4":2840,"NA":2842},{"trials":2829,"activeCount":95},[],{"trials":2831,"activeCount":95},[],{"trials":2833,"activeCount":95},[],{"trials":2835,"activeCount":95},[2836],{"nctId":2813,"briefTitle":2814,"status":101,"phases":2837,"primaryCompletion":2816,"completion":2817,"start":2411,"enrollment":2553,"conditions":2838,"interventions":2839},[87],[20],[2802,2820,2821],{"trials":2841,"activeCount":95},[],{"trials":2843,"activeCount":95},[],{"intervention":2821,"totalTrials":135,"cells":2845},{"EARLY_PHASE1":2846,"PHASE1":2848,"PHASE2":2850,"PHASE3":2852,"PHASE4":2858,"NA":2860},{"trials":2847,"activeCount":95},[],{"trials":2849,"activeCount":95},[],{"trials":2851,"activeCount":95},[],{"trials":2853,"activeCount":95},[2854],{"nctId":2813,"briefTitle":2814,"status":101,"phases":2855,"primaryCompletion":2816,"completion":2817,"start":2411,"enrollment":2553,"conditions":2856,"interventions":2857},[87],[20],[2802,2820,2821],{"trials":2859,"activeCount":95},[],{"trials":2861,"activeCount":95},[],{"intervention":2863,"totalTrials":135,"cells":2864},"Budesonide Foam",{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2869,"PHASE3":2871,"PHASE4":2882,"NA":2884},{"trials":2866,"activeCount":95},[],{"trials":2868,"activeCount":95},[],{"trials":2870,"activeCount":95},[],{"trials":2872,"activeCount":95},[2873],{"nctId":2874,"briefTitle":2875,"status":600,"phases":2876,"primaryCompletion":2877,"completion":2877,"start":2878,"enrollment":2879,"conditions":2880,"interventions":2881},"NCT01349673","The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis",[87],"2014-12-31","2011-05-31",114,[1804,1805],[2863],{"trials":2883,"activeCount":95},[],{"trials":2885,"activeCount":95},[],{"intervention":1891,"totalTrials":135,"cells":2887},{"EARLY_PHASE1":2888,"PHASE1":2890,"PHASE2":2892,"PHASE3":2894,"PHASE4":2900,"NA":2902},{"trials":2889,"activeCount":95},[],{"trials":2891,"activeCount":95},[],{"trials":2893,"activeCount":95},[],{"trials":2895,"activeCount":95},[2896],{"nctId":1885,"briefTitle":1886,"status":101,"phases":2897,"primaryCompletion":1328,"completion":1328,"start":1888,"enrollment":1878,"conditions":2898,"interventions":2899},[87],[1880],[1854,1882,1891],{"trials":2901,"activeCount":95},[],{"trials":2903,"activeCount":95},[],{"intervention":2905,"totalTrials":135,"cells":2906},"Crofelemer 125 mg",{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2911,"PHASE3":2913,"PHASE4":2926,"NA":2928},{"trials":2908,"activeCount":95},[],{"trials":2910,"activeCount":95},[],{"trials":2912,"activeCount":95},[],{"trials":2914,"activeCount":95},[2915],{"nctId":2916,"briefTitle":2917,"status":101,"phases":2918,"primaryCompletion":2919,"completion":2920,"start":1210,"enrollment":1268,"conditions":2921,"interventions":2923},"NCT00547898","Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea",[87],"2011-01-27","2011-07-11",[2922],"HIV Associated Diarrhea",[2905,2924,2925],"Crofelemer 250 mg","Crofelemer 500 mg",{"trials":2927,"activeCount":95},[],{"trials":2929,"activeCount":95},[],{"intervention":2924,"totalTrials":135,"cells":2931},{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2936,"PHASE3":2938,"PHASE4":2944,"NA":2946},{"trials":2933,"activeCount":95},[],{"trials":2935,"activeCount":95},[],{"trials":2937,"activeCount":95},[],{"trials":2939,"activeCount":95},[2940],{"nctId":2916,"briefTitle":2917,"status":101,"phases":2941,"primaryCompletion":2919,"completion":2920,"start":1210,"enrollment":1268,"conditions":2942,"interventions":2943},[87],[2922],[2905,2924,2925],{"trials":2945,"activeCount":95},[],{"trials":2947,"activeCount":95},[],{"intervention":2925,"totalTrials":135,"cells":2949},{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2954,"PHASE3":2956,"PHASE4":2962,"NA":2964},{"trials":2951,"activeCount":95},[],{"trials":2953,"activeCount":95},[],{"trials":2955,"activeCount":95},[],{"trials":2957,"activeCount":95},[2958],{"nctId":2916,"briefTitle":2917,"status":101,"phases":2959,"primaryCompletion":2919,"completion":2920,"start":1210,"enrollment":1268,"conditions":2960,"interventions":2961},[87],[2922],[2905,2924,2925],{"trials":2963,"activeCount":95},[],{"trials":2965,"activeCount":95},[],{"intervention":2967,"totalTrials":135,"cells":2968},"tramadol HCl ER; celecoxib",{"EARLY_PHASE1":2969,"PHASE1":2971,"PHASE2":2973,"PHASE3":2975,"PHASE4":2985,"NA":2987},{"trials":2970,"activeCount":95},[],{"trials":2972,"activeCount":95},[],{"trials":2974,"activeCount":95},[],{"trials":2976,"activeCount":95},[2977],{"nctId":2978,"briefTitle":2979,"status":101,"phases":2980,"completion":2981,"start":2982,"enrollment":1952,"conditions":2983,"interventions":2984},"NCT00348452","A Study Comparing the Effectiveness and Safety of Extended Release Tramadol HCl at 100 mg, 200 mg and 300 mg Doses to Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis (OA)",[87],"2003-08","2002-09",[1945],[2967],{"trials":2986,"activeCount":95},[],{"trials":2988,"activeCount":95},[],{"intervention":1299,"totalTrials":31,"cells":2990},{"EARLY_PHASE1":2991,"PHASE1":2993,"PHASE2":3020,"PHASE3":3040,"PHASE4":3042,"NA":3044},{"trials":2992,"activeCount":95},[],{"trials":2994,"activeCount":95},[2995,3004,3012,3016],{"nctId":2996,"briefTitle":2997,"status":101,"phases":2998,"primaryCompletion":2749,"completion":2749,"start":2999,"enrollment":11,"conditions":3000,"interventions":3002},"NCT01367561","Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function",[85],"2002-10",[3001],"Healthy Males",[3003,1299],"Naloxone",{"nctId":3005,"briefTitle":3006,"status":101,"phases":3007,"primaryCompletion":591,"completion":591,"start":591,"enrollment":31,"conditions":3008,"interventions":3010},"NCT01367483","Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX",[85],[3009],"Healthy Male Volunteers",[3011],"IV methylnaltrexone",{"nctId":1293,"briefTitle":1294,"status":101,"phases":3013,"primaryCompletion":1224,"completion":1224,"start":1231,"enrollment":338,"conditions":3014,"interventions":3015},[85],[1297],[1277,1299,1300,1301],{"nctId":1303,"briefTitle":1304,"status":101,"phases":3017,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":31,"conditions":3018,"interventions":3019},[85],[1309],[1277,1277,1277,1299],{"trials":3021,"activeCount":95},[3022,3031],{"nctId":3023,"briefTitle":3024,"status":101,"phases":3025,"primaryCompletion":3026,"completion":3026,"start":3027,"enrollment":500,"conditions":3028,"interventions":3030},"NCT01367587","Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone",[86],"2002-07","2002-04",[3029],"Healthy Volunteers",[1299],{"nctId":3032,"briefTitle":3033,"status":101,"phases":3034,"primaryCompletion":1754,"completion":1754,"start":3035,"enrollment":3036,"conditions":3037,"interventions":3039},"NCT01367548","Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus",[86],"2003-07",65,[3038],"Postoperative Ileus",[1299],{"trials":3041,"activeCount":95},[],{"trials":3043,"activeCount":95},[],{"trials":3045,"activeCount":95},[],{"intervention":647,"totalTrials":168,"cells":3047},{"EARLY_PHASE1":3048,"PHASE1":3050,"PHASE2":3060,"PHASE3":3070,"PHASE4":3072,"NA":3074},{"trials":3049,"activeCount":95},[],{"trials":3051,"activeCount":95},[3052,3056],{"nctId":1585,"briefTitle":1586,"status":101,"phases":3053,"primaryCompletion":641,"completion":181,"start":182,"enrollment":1232,"conditions":3054,"interventions":3055},[85],[30],[892,647],{"nctId":638,"briefTitle":639,"status":101,"phases":3057,"primaryCompletion":641,"completion":181,"start":642,"enrollment":643,"conditions":3058,"interventions":3059},[85],[18],[630,646,188,647],{"trials":3061,"activeCount":95},[3062,3066],{"nctId":884,"briefTitle":885,"status":101,"phases":3063,"primaryCompletion":887,"completion":888,"start":889,"enrollment":592,"conditions":3064,"interventions":3065},[86],[15],[892,647,893,861],{"nctId":661,"briefTitle":662,"status":101,"phases":3067,"primaryCompletion":664,"completion":641,"start":665,"enrollment":666,"conditions":3068,"interventions":3069},[86],[18],[630,647,658,659],{"trials":3071,"activeCount":95},[],{"trials":3073,"activeCount":95},[],{"trials":3075,"activeCount":95},[],{"intervention":188,"totalTrials":1676,"cells":3077},{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3086,"PHASE3":3096,"PHASE4":3098,"NA":3100},{"trials":3079,"activeCount":95},[],{"trials":3081,"activeCount":95},[3082],{"nctId":638,"briefTitle":639,"status":101,"phases":3083,"primaryCompletion":641,"completion":181,"start":642,"enrollment":643,"conditions":3084,"interventions":3085},[85],[18],[630,646,188,647],{"trials":3087,"activeCount":95},[3088,3092],{"nctId":651,"briefTitle":652,"status":101,"phases":3089,"primaryCompletion":641,"completion":181,"start":654,"enrollment":655,"conditions":3090,"interventions":3091},[86],[18],[658,659,630,188],{"nctId":177,"briefTitle":178,"status":101,"phases":3093,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":3094,"interventions":3095},[86],[18],[186,187,53,188],{"trials":3097,"activeCount":95},[],{"trials":3099,"activeCount":95},[],{"trials":3101,"activeCount":95},[],{"intervention":659,"totalTrials":132,"cells":3103},{"EARLY_PHASE1":3104,"PHASE1":3106,"PHASE2":3108,"PHASE3":3118,"PHASE4":3120,"NA":3122},{"trials":3105,"activeCount":95},[],{"trials":3107,"activeCount":95},[],{"trials":3109,"activeCount":95},[3110,3114],{"nctId":651,"briefTitle":652,"status":101,"phases":3111,"primaryCompletion":641,"completion":181,"start":654,"enrollment":655,"conditions":3112,"interventions":3113},[86],[18],[658,659,630,188],{"nctId":661,"briefTitle":662,"status":101,"phases":3115,"primaryCompletion":664,"completion":641,"start":665,"enrollment":666,"conditions":3116,"interventions":3117},[86],[18],[630,647,658,659],{"trials":3119,"activeCount":95},[],{"trials":3121,"activeCount":95},[],{"trials":3123,"activeCount":95},[],{"intervention":3125,"totalTrials":132,"cells":3126},"140 mg SC",{"EARLY_PHASE1":3127,"PHASE1":3129,"PHASE2":3140,"PHASE3":3153,"PHASE4":3155,"NA":3157},{"trials":3128,"activeCount":95},[],{"trials":3130,"activeCount":95},[3131],{"nctId":3132,"briefTitle":3133,"status":101,"phases":3134,"primaryCompletion":556,"completion":556,"start":1186,"enrollment":3135,"conditions":3136,"interventions":3137},"NCT00867100","Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827",[85],84,[18],[3138,3139,3125],"700 mg IV","350 mg SC",{"trials":3141,"activeCount":95},[3142],{"nctId":3143,"briefTitle":3144,"status":101,"phases":3145,"primaryCompletion":732,"completion":2386,"start":3146,"enrollment":3147,"conditions":3148,"interventions":3149},"NCT00975637","Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis",[86],"2009-12",198,[18],[3150,3151,3125,3152],"70 mg SC","210 mg SC","280 mg SC",{"trials":3154,"activeCount":95},[],{"trials":3156,"activeCount":95},[],{"trials":3158,"activeCount":95},[],{"intervention":3160,"totalTrials":132,"cells":3161},"pradefovir mesylate",{"EARLY_PHASE1":3162,"PHASE1":3164,"PHASE2":3166,"PHASE3":3183,"PHASE4":3185,"NA":3187},{"trials":3163,"activeCount":95},[],{"trials":3165,"activeCount":95},[],{"trials":3167,"activeCount":95},[3168,3176],{"nctId":3169,"briefTitle":3170,"status":600,"phases":3171,"completion":1202,"start":591,"enrollment":183,"conditions":3172,"interventions":3174},"NCT00230490","Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201",[86],[3173],"Hepatitis B, Chronic",[3160,3175],"adefovir dipivoxyl",{"nctId":3177,"briefTitle":3178,"status":101,"phases":3179,"primaryCompletion":566,"completion":566,"start":1877,"enrollment":3180,"conditions":3181,"interventions":3182},"NCT00230503","Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B",[86],220,[3173],[3160,3175],{"trials":3184,"activeCount":95},[],{"trials":3186,"activeCount":95},[],{"trials":3188,"activeCount":95},[],{"intervention":3175,"totalTrials":132,"cells":3190},{"EARLY_PHASE1":3191,"PHASE1":3193,"PHASE2":3195,"PHASE3":3205,"PHASE4":3207,"NA":3209},{"trials":3192,"activeCount":95},[],{"trials":3194,"activeCount":95},[],{"trials":3196,"activeCount":95},[3197,3201],{"nctId":3169,"briefTitle":3170,"status":600,"phases":3198,"completion":1202,"start":591,"enrollment":183,"conditions":3199,"interventions":3200},[86],[3173],[3160,3175],{"nctId":3177,"briefTitle":3178,"status":101,"phases":3202,"primaryCompletion":566,"completion":566,"start":1877,"enrollment":3180,"conditions":3203,"interventions":3204},[86],[3173],[3160,3175],{"trials":3206,"activeCount":95},[],{"trials":3208,"activeCount":95},[],{"trials":3210,"activeCount":95},[],{"intervention":3212,"totalTrials":135,"cells":3213},"Rifaximin SSD 40 mg IR",{"EARLY_PHASE1":3214,"PHASE1":3216,"PHASE2":3218,"PHASE3":3233,"PHASE4":3235,"NA":3237},{"trials":3215,"activeCount":95},[],{"trials":3217,"activeCount":95},[],{"trials":3219,"activeCount":95},[3220],{"nctId":3221,"briefTitle":3222,"status":101,"phases":3223,"primaryCompletion":2657,"completion":3224,"start":3225,"enrollment":1249,"conditions":3226,"interventions":3228},"NCT01904409","Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis",[86],"2015-07","2013-06",[3227],"Liver Cirrhosis",[3212,3229,3230,3231,3232],"Rifaximin SSD 80 mg IR","Rifaximin SSD 40 mg SER","Rifaximin SSD 80 mg SER","Rifaximin SSD 80mgIR\u002F80mgSER",{"trials":3234,"activeCount":95},[],{"trials":3236,"activeCount":95},[],{"trials":3238,"activeCount":95},[],{"intervention":3229,"totalTrials":135,"cells":3240},{"EARLY_PHASE1":3241,"PHASE1":3243,"PHASE2":3245,"PHASE3":3251,"PHASE4":3253,"NA":3255},{"trials":3242,"activeCount":95},[],{"trials":3244,"activeCount":95},[],{"trials":3246,"activeCount":95},[3247],{"nctId":3221,"briefTitle":3222,"status":101,"phases":3248,"primaryCompletion":2657,"completion":3224,"start":3225,"enrollment":1249,"conditions":3249,"interventions":3250},[86],[3227],[3212,3229,3230,3231,3232],{"trials":3252,"activeCount":95},[],{"trials":3254,"activeCount":95},[],{"trials":3256,"activeCount":95},[],{"intervention":3230,"totalTrials":135,"cells":3258},{"EARLY_PHASE1":3259,"PHASE1":3261,"PHASE2":3263,"PHASE3":3269,"PHASE4":3271,"NA":3273},{"trials":3260,"activeCount":95},[],{"trials":3262,"activeCount":95},[],{"trials":3264,"activeCount":95},[3265],{"nctId":3221,"briefTitle":3222,"status":101,"phases":3266,"primaryCompletion":2657,"completion":3224,"start":3225,"enrollment":1249,"conditions":3267,"interventions":3268},[86],[3227],[3212,3229,3230,3231,3232],{"trials":3270,"activeCount":95},[],{"trials":3272,"activeCount":95},[],{"trials":3274,"activeCount":95},[],{"intervention":3231,"totalTrials":135,"cells":3276},{"EARLY_PHASE1":3277,"PHASE1":3279,"PHASE2":3281,"PHASE3":3287,"PHASE4":3289,"NA":3291},{"trials":3278,"activeCount":95},[],{"trials":3280,"activeCount":95},[],{"trials":3282,"activeCount":95},[3283],{"nctId":3221,"briefTitle":3222,"status":101,"phases":3284,"primaryCompletion":2657,"completion":3224,"start":3225,"enrollment":1249,"conditions":3285,"interventions":3286},[86],[3227],[3212,3229,3230,3231,3232],{"trials":3288,"activeCount":95},[],{"trials":3290,"activeCount":95},[],{"trials":3292,"activeCount":95},[],{"intervention":3232,"totalTrials":135,"cells":3294},{"EARLY_PHASE1":3295,"PHASE1":3297,"PHASE2":3299,"PHASE3":3305,"PHASE4":3307,"NA":3309},{"trials":3296,"activeCount":95},[],{"trials":3298,"activeCount":95},[],{"trials":3300,"activeCount":95},[3301],{"nctId":3221,"briefTitle":3222,"status":101,"phases":3302,"primaryCompletion":2657,"completion":3224,"start":3225,"enrollment":1249,"conditions":3303,"interventions":3304},[86],[3227],[3212,3229,3230,3231,3232],{"trials":3306,"activeCount":95},[],{"trials":3308,"activeCount":95},[],{"trials":3310,"activeCount":95},[],{"intervention":1383,"totalTrials":135,"cells":3312},{"EARLY_PHASE1":3313,"PHASE1":3315,"PHASE2":3317,"PHASE3":3323,"PHASE4":3325,"NA":3327},{"trials":3314,"activeCount":95},[],{"trials":3316,"activeCount":95},[],{"trials":3318,"activeCount":95},[3319],{"nctId":1374,"briefTitle":1375,"status":101,"phases":3320,"primaryCompletion":1377,"completion":1377,"start":1378,"enrollment":1379,"conditions":3321,"interventions":3322},[86],[15],[1355,1382,1383],{"trials":3324,"activeCount":95},[],{"trials":3326,"activeCount":95},[],{"trials":3328,"activeCount":95},[],{"intervention":3330,"totalTrials":135,"cells":3331},"SAN-300 0.5 mg\u002Fkg QW",{"EARLY_PHASE1":3332,"PHASE1":3334,"PHASE2":3336,"PHASE3":3352,"PHASE4":3354,"NA":3356},{"trials":3333,"activeCount":95},[],{"trials":3335,"activeCount":95},[],{"trials":3337,"activeCount":95},[3338],{"nctId":3339,"briefTitle":3340,"status":101,"phases":3341,"primaryCompletion":1981,"completion":3342,"start":3343,"enrollment":3344,"conditions":3345,"interventions":3347},"NCT02047604","(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis",[86],"2017-03-23","2013-12",41,[3346],"Rheumatoid Arthritis",[3330,3348,3349,3350,3351],"SAN-300 1.0 mg\u002Fkg QW","SAN-300 2.0 mg\u002Fkg QOW","SAN-300 4.0 mg\u002Fkg QOW","SAN-300 4.0 mg\u002Fkg QW",{"trials":3353,"activeCount":95},[],{"trials":3355,"activeCount":95},[],{"trials":3357,"activeCount":95},[],{"intervention":3348,"totalTrials":135,"cells":3359},{"EARLY_PHASE1":3360,"PHASE1":3362,"PHASE2":3364,"PHASE3":3370,"PHASE4":3372,"NA":3374},{"trials":3361,"activeCount":95},[],{"trials":3363,"activeCount":95},[],{"trials":3365,"activeCount":95},[3366],{"nctId":3339,"briefTitle":3340,"status":101,"phases":3367,"primaryCompletion":1981,"completion":3342,"start":3343,"enrollment":3344,"conditions":3368,"interventions":3369},[86],[3346],[3330,3348,3349,3350,3351],{"trials":3371,"activeCount":95},[],{"trials":3373,"activeCount":95},[],{"trials":3375,"activeCount":95},[],{"intervention":3349,"totalTrials":135,"cells":3377},{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3388,"PHASE4":3390,"NA":3392},{"trials":3379,"activeCount":95},[],{"trials":3381,"activeCount":95},[],{"trials":3383,"activeCount":95},[3384],{"nctId":3339,"briefTitle":3340,"status":101,"phases":3385,"primaryCompletion":1981,"completion":3342,"start":3343,"enrollment":3344,"conditions":3386,"interventions":3387},[86],[3346],[3330,3348,3349,3350,3351],{"trials":3389,"activeCount":95},[],{"trials":3391,"activeCount":95},[],{"trials":3393,"activeCount":95},[],{"intervention":3350,"totalTrials":135,"cells":3395},{"EARLY_PHASE1":3396,"PHASE1":3398,"PHASE2":3400,"PHASE3":3406,"PHASE4":3408,"NA":3410},{"trials":3397,"activeCount":95},[],{"trials":3399,"activeCount":95},[],{"trials":3401,"activeCount":95},[3402],{"nctId":3339,"briefTitle":3340,"status":101,"phases":3403,"primaryCompletion":1981,"completion":3342,"start":3343,"enrollment":3344,"conditions":3404,"interventions":3405},[86],[3346],[3330,3348,3349,3350,3351],{"trials":3407,"activeCount":95},[],{"trials":3409,"activeCount":95},[],{"trials":3411,"activeCount":95},[],{"intervention":3351,"totalTrials":135,"cells":3413},{"EARLY_PHASE1":3414,"PHASE1":3416,"PHASE2":3418,"PHASE3":3424,"PHASE4":3426,"NA":3428},{"trials":3415,"activeCount":95},[],{"trials":3417,"activeCount":95},[],{"trials":3419,"activeCount":95},[3420],{"nctId":3339,"briefTitle":3340,"status":101,"phases":3421,"primaryCompletion":1981,"completion":3342,"start":3343,"enrollment":3344,"conditions":3422,"interventions":3423},[86],[3346],[3330,3348,3349,3350,3351],{"trials":3425,"activeCount":95},[],{"trials":3427,"activeCount":95},[],{"trials":3429,"activeCount":95},[],{"intervention":3431,"totalTrials":135,"cells":3432},"SP-333 1 mg",{"EARLY_PHASE1":3433,"PHASE1":3435,"PHASE2":3437,"PHASE3":3448,"PHASE4":3450,"NA":3452},{"trials":3434,"activeCount":95},[],{"trials":3436,"activeCount":95},[],{"trials":3438,"activeCount":95},[3439],{"nctId":3440,"briefTitle":3441,"status":101,"phases":3442,"primaryCompletion":114,"completion":642,"start":2658,"enrollment":3443,"conditions":3444,"interventions":3445},"NCT01983306","Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)",[86],292,[22],[3431,3446,3447],"SP-333 3 mg","SP-333 6 mg",{"trials":3449,"activeCount":95},[],{"trials":3451,"activeCount":95},[],{"trials":3453,"activeCount":95},[],{"intervention":3446,"totalTrials":135,"cells":3455},{"EARLY_PHASE1":3456,"PHASE1":3458,"PHASE2":3460,"PHASE3":3466,"PHASE4":3468,"NA":3470},{"trials":3457,"activeCount":95},[],{"trials":3459,"activeCount":95},[],{"trials":3461,"activeCount":95},[3462],{"nctId":3440,"briefTitle":3441,"status":101,"phases":3463,"primaryCompletion":114,"completion":642,"start":2658,"enrollment":3443,"conditions":3464,"interventions":3465},[86],[22],[3431,3446,3447],{"trials":3467,"activeCount":95},[],{"trials":3469,"activeCount":95},[],{"trials":3471,"activeCount":95},[],{"intervention":3447,"totalTrials":135,"cells":3473},{"EARLY_PHASE1":3474,"PHASE1":3476,"PHASE2":3478,"PHASE3":3484,"PHASE4":3486,"NA":3488},{"trials":3475,"activeCount":95},[],{"trials":3477,"activeCount":95},[],{"trials":3479,"activeCount":95},[3480],{"nctId":3440,"briefTitle":3441,"status":101,"phases":3481,"primaryCompletion":114,"completion":642,"start":2658,"enrollment":3443,"conditions":3482,"interventions":3483},[86],[22],[3431,3446,3447],{"trials":3485,"activeCount":95},[],{"trials":3487,"activeCount":95},[],{"trials":3489,"activeCount":95},[],{"intervention":3491,"totalTrials":135,"cells":3492},"Low Dose MT-1303",{"EARLY_PHASE1":3493,"PHASE1":3495,"PHASE2":3497,"PHASE3":3510,"PHASE4":3512,"NA":3514},{"trials":3494,"activeCount":95},[],{"trials":3496,"activeCount":95},[],{"trials":3498,"activeCount":95},[3499],{"nctId":3500,"briefTitle":3501,"status":101,"phases":3502,"primaryCompletion":3503,"completion":3504,"start":3505,"enrollment":538,"conditions":3506,"interventions":3507},"NCT04857112","Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis",[86],"2024-09-03","2024-11-08","2021-09-29",[20],[3491,3508,3509],"High Dose MT-1303","MT-1303",{"trials":3511,"activeCount":95},[],{"trials":3513,"activeCount":95},[],{"trials":3515,"activeCount":95},[],{"intervention":3508,"totalTrials":135,"cells":3517},{"EARLY_PHASE1":3518,"PHASE1":3520,"PHASE2":3522,"PHASE3":3528,"PHASE4":3530,"NA":3532},{"trials":3519,"activeCount":95},[],{"trials":3521,"activeCount":95},[],{"trials":3523,"activeCount":95},[3524],{"nctId":3500,"briefTitle":3501,"status":101,"phases":3525,"primaryCompletion":3503,"completion":3504,"start":3505,"enrollment":538,"conditions":3526,"interventions":3527},[86],[20],[3491,3508,3509],{"trials":3529,"activeCount":95},[],{"trials":3531,"activeCount":95},[],{"trials":3533,"activeCount":95},[],{"intervention":3509,"totalTrials":135,"cells":3535},{"EARLY_PHASE1":3536,"PHASE1":3538,"PHASE2":3540,"PHASE3":3546,"PHASE4":3548,"NA":3550},{"trials":3537,"activeCount":95},[],{"trials":3539,"activeCount":95},[],{"trials":3541,"activeCount":95},[3542],{"nctId":3500,"briefTitle":3501,"status":101,"phases":3543,"primaryCompletion":3503,"completion":3504,"start":3505,"enrollment":538,"conditions":3544,"interventions":3545},[86],[20],[3491,3508,3509],{"trials":3547,"activeCount":95},[],{"trials":3549,"activeCount":95},[],{"trials":3551,"activeCount":95},[],{"intervention":893,"totalTrials":135,"cells":3553},{"EARLY_PHASE1":3554,"PHASE1":3556,"PHASE2":3558,"PHASE3":3564,"PHASE4":3566,"NA":3568},{"trials":3555,"activeCount":95},[],{"trials":3557,"activeCount":95},[],{"trials":3559,"activeCount":95},[3560],{"nctId":884,"briefTitle":885,"status":101,"phases":3561,"primaryCompletion":887,"completion":888,"start":889,"enrollment":592,"conditions":3562,"interventions":3563},[86],[15],[892,647,893,861],{"trials":3565,"activeCount":95},[],{"trials":3567,"activeCount":95},[],{"trials":3569,"activeCount":95},[],{"intervention":3571,"totalTrials":135,"cells":3572},"AMG 827",{"EARLY_PHASE1":3573,"PHASE1":3575,"PHASE2":3577,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3574,"activeCount":95},[],{"trials":3576,"activeCount":95},[],{"trials":3578,"activeCount":95},[3579],{"nctId":3580,"briefTitle":3581,"status":600,"phases":3582,"primaryCompletion":2282,"completion":2282,"start":2410,"enrollment":3583,"conditions":3584,"interventions":3585},"NCT01101100","Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis",[86],181,[18],[3571],{"trials":3587,"activeCount":95},[],{"trials":3589,"activeCount":95},[],{"trials":3591,"activeCount":95},[],{"intervention":3593,"totalTrials":135,"cells":3594},"40 mg Rifaximin SSD once daily",{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3599,"PHASE3":3614,"PHASE4":3616,"NA":3618},{"trials":3596,"activeCount":95},[],{"trials":3598,"activeCount":95},[],{"trials":3600,"activeCount":95},[3601],{"nctId":3602,"briefTitle":3603,"status":101,"phases":3604,"primaryCompletion":3605,"completion":3605,"start":3606,"enrollment":3607,"conditions":3608,"interventions":3610},"NCT03515044","Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)",[86],"2020-03-12","2018-09-13",71,[3609],"Overt Hepatic Encephalopathy",[3593,3611,3612,3613],"40 mg Rifaximin SSD twice daily","80 mg Rifaximin SSD once daily","80 mg Rifaximin SSD twice daily",{"trials":3615,"activeCount":95},[],{"trials":3617,"activeCount":95},[],{"trials":3619,"activeCount":95},[],{"intervention":3611,"totalTrials":135,"cells":3621},{"EARLY_PHASE1":3622,"PHASE1":3624,"PHASE2":3626,"PHASE3":3632,"PHASE4":3634,"NA":3636},{"trials":3623,"activeCount":95},[],{"trials":3625,"activeCount":95},[],{"trials":3627,"activeCount":95},[3628],{"nctId":3602,"briefTitle":3603,"status":101,"phases":3629,"primaryCompletion":3605,"completion":3605,"start":3606,"enrollment":3607,"conditions":3630,"interventions":3631},[86],[3609],[3593,3611,3612,3613],{"trials":3633,"activeCount":95},[],{"trials":3635,"activeCount":95},[],{"trials":3637,"activeCount":95},[],{"intervention":3612,"totalTrials":135,"cells":3639},{"EARLY_PHASE1":3640,"PHASE1":3642,"PHASE2":3644,"PHASE3":3650,"PHASE4":3652,"NA":3654},{"trials":3641,"activeCount":95},[],{"trials":3643,"activeCount":95},[],{"trials":3645,"activeCount":95},[3646],{"nctId":3602,"briefTitle":3603,"status":101,"phases":3647,"primaryCompletion":3605,"completion":3605,"start":3606,"enrollment":3607,"conditions":3648,"interventions":3649},[86],[3609],[3593,3611,3612,3613],{"trials":3651,"activeCount":95},[],{"trials":3653,"activeCount":95},[],{"trials":3655,"activeCount":95},[],{"intervention":3613,"totalTrials":135,"cells":3657},{"EARLY_PHASE1":3658,"PHASE1":3660,"PHASE2":3662,"PHASE3":3668,"PHASE4":3670,"NA":3672},{"trials":3659,"activeCount":95},[],{"trials":3661,"activeCount":95},[],{"trials":3663,"activeCount":95},[3664],{"nctId":3602,"briefTitle":3603,"status":101,"phases":3665,"primaryCompletion":3605,"completion":3605,"start":3606,"enrollment":3607,"conditions":3666,"interventions":3667},[86],[3609],[3593,3611,3612,3613],{"trials":3669,"activeCount":95},[],{"trials":3671,"activeCount":95},[],{"trials":3673,"activeCount":95},[],{"intervention":1869,"totalTrials":135,"cells":3675},{"EARLY_PHASE1":3676,"PHASE1":3678,"PHASE2":3680,"PHASE3":3686,"PHASE4":3688,"NA":3690},{"trials":3677,"activeCount":95},[],{"trials":3679,"activeCount":95},[],{"trials":3681,"activeCount":95},[3682],{"nctId":1863,"briefTitle":1864,"status":600,"phases":3683,"completion":1202,"start":1753,"enrollment":279,"conditions":3684,"interventions":3685},[86],[1867],[1854,1869],{"trials":3687,"activeCount":95},[],{"trials":3689,"activeCount":95},[],{"trials":3691,"activeCount":95},[],{"intervention":3693,"totalTrials":135,"cells":3694},"Retin-A Micro 0.04% facial acne treatment",{"EARLY_PHASE1":3695,"PHASE1":3697,"PHASE2":3699,"PHASE3":3709,"PHASE4":3711,"NA":3713},{"trials":3696,"activeCount":95},[],{"trials":3698,"activeCount":95},[],{"trials":3700,"activeCount":95},[3701],{"nctId":3702,"briefTitle":3703,"status":101,"phases":3704,"primaryCompletion":3146,"completion":3146,"start":810,"enrollment":3705,"conditions":3706,"interventions":3707},"NCT00907335","A Study of Acne Treatment in Children Ages 9 to 11",[86],110,[15],[3693,3708],"Vehicle control",{"trials":3710,"activeCount":95},[],{"trials":3712,"activeCount":95},[],{"trials":3714,"activeCount":95},[],{"intervention":3708,"totalTrials":135,"cells":3716},{"EARLY_PHASE1":3717,"PHASE1":3719,"PHASE2":3721,"PHASE3":3727,"PHASE4":3729,"NA":3731},{"trials":3718,"activeCount":95},[],{"trials":3720,"activeCount":95},[],{"trials":3722,"activeCount":95},[3723],{"nctId":3702,"briefTitle":3703,"status":101,"phases":3724,"primaryCompletion":3146,"completion":3146,"start":810,"enrollment":3705,"conditions":3725,"interventions":3726},[86],[15],[3693,3708],{"trials":3728,"activeCount":95},[],{"trials":3730,"activeCount":95},[],{"trials":3732,"activeCount":95},[],{"intervention":3734,"totalTrials":135,"cells":3735},"Mesalamine Granules 750 mg",{"EARLY_PHASE1":3736,"PHASE1":3738,"PHASE2":3740,"PHASE3":3751,"PHASE4":3753,"NA":3755},{"trials":3737,"activeCount":95},[],{"trials":3739,"activeCount":95},[],{"trials":3741,"activeCount":95},[3742],{"nctId":3743,"briefTitle":3744,"status":101,"phases":3745,"primaryCompletion":3746,"completion":3746,"start":732,"enrollment":3747,"conditions":3748,"interventions":3749},"NCT01177410","Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea",[86],"2011-08",148,[2598],[3734,3750],"Mesalamine Granules 1500 mg",{"trials":3752,"activeCount":95},[],{"trials":3754,"activeCount":95},[],{"trials":3756,"activeCount":95},[],{"intervention":3750,"totalTrials":135,"cells":3758},{"EARLY_PHASE1":3759,"PHASE1":3761,"PHASE2":3763,"PHASE3":3769,"PHASE4":3771,"NA":3773},{"trials":3760,"activeCount":95},[],{"trials":3762,"activeCount":95},[],{"trials":3764,"activeCount":95},[3765],{"nctId":3743,"briefTitle":3744,"status":101,"phases":3766,"primaryCompletion":3746,"completion":3746,"start":732,"enrollment":3747,"conditions":3767,"interventions":3768},[86],[2598],[3734,3750],{"trials":3770,"activeCount":95},[],{"trials":3772,"activeCount":95},[],{"trials":3774,"activeCount":95},[],{"intervention":3776,"totalTrials":135,"cells":3777},"SC MNTX",{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3782,"PHASE3":3792,"PHASE4":3794,"NA":3796},{"trials":3779,"activeCount":95},[],{"trials":3781,"activeCount":95},[],{"trials":3783,"activeCount":95},[3784],{"nctId":3785,"briefTitle":3786,"status":101,"phases":3787,"primaryCompletion":2749,"completion":2749,"start":3027,"enrollment":3788,"conditions":3789,"interventions":3791},"NCT01367574","Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction",[86],39,[3790],"Bowel Dysfunction",[3776,3776,3776],{"trials":3793,"activeCount":95},[],{"trials":3795,"activeCount":95},[],{"trials":3797,"activeCount":95},[],{"intervention":3799,"totalTrials":135,"cells":3800},"Retigabine",{"EARLY_PHASE1":3801,"PHASE1":3803,"PHASE2":3805,"PHASE3":3815,"PHASE4":3817,"NA":3819},{"trials":3802,"activeCount":95},[],{"trials":3804,"activeCount":95},[],{"trials":3806,"activeCount":95},[3807],{"nctId":3808,"briefTitle":3809,"status":101,"phases":3810,"primaryCompletion":830,"completion":3146,"start":1210,"enrollment":3811,"conditions":3812,"interventions":3814},"NCT00612105","Safety\u002FEfficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)",[86],187,[3813],"Postherpetic Neuralgia",[3799],{"trials":3816,"activeCount":95},[],{"trials":3818,"activeCount":95},[],{"trials":3820,"activeCount":95},[],{"intervention":3822,"totalTrials":135,"cells":3823},"Metyrosine",{"EARLY_PHASE1":3824,"PHASE1":3826,"PHASE2":3828,"PHASE3":3840,"PHASE4":3842,"NA":3844},{"trials":3825,"activeCount":95},[],{"trials":3827,"activeCount":95},[],{"trials":3829,"activeCount":95},[3830],{"nctId":3831,"briefTitle":3832,"status":600,"phases":3833,"primaryCompletion":3834,"completion":3835,"start":2817,"enrollment":132,"conditions":3836,"interventions":3839},"NCT01127503","Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome",[86],"2010-11","2011-09",[3837,3838],"Velo-cardio-facial Syndrome","Psychosis",[3822],{"trials":3841,"activeCount":95},[],{"trials":3843,"activeCount":95},[],{"trials":3845,"activeCount":95},[],{"intervention":3847,"totalTrials":135,"cells":3848},"1.2% JNJ 10229570-AAA",{"EARLY_PHASE1":3849,"PHASE1":3851,"PHASE2":3853,"PHASE3":3866,"PHASE4":3868,"NA":3870},{"trials":3850,"activeCount":95},[],{"trials":3852,"activeCount":95},[],{"trials":3854,"activeCount":95},[3855],{"nctId":3856,"briefTitle":3857,"status":101,"phases":3858,"primaryCompletion":3859,"completion":3859,"start":3860,"enrollment":3861,"conditions":3862,"interventions":3863},"NCT01326780","A Study of a New Drug Treatment for Acne",[86],"2012-03-31","2011-03-31",431,[15],[3847,3864,3865],"2.4% JNJ 10229570-AAA","3.6% JNJ 10229570-AAA",{"trials":3867,"activeCount":95},[],{"trials":3869,"activeCount":95},[],{"trials":3871,"activeCount":95},[],{"intervention":3864,"totalTrials":135,"cells":3873},{"EARLY_PHASE1":3874,"PHASE1":3876,"PHASE2":3878,"PHASE3":3884,"PHASE4":3886,"NA":3888},{"trials":3875,"activeCount":95},[],{"trials":3877,"activeCount":95},[],{"trials":3879,"activeCount":95},[3880],{"nctId":3856,"briefTitle":3857,"status":101,"phases":3881,"primaryCompletion":3859,"completion":3859,"start":3860,"enrollment":3861,"conditions":3882,"interventions":3883},[86],[15],[3847,3864,3865],{"trials":3885,"activeCount":95},[],{"trials":3887,"activeCount":95},[],{"trials":3889,"activeCount":95},[],{"intervention":3865,"totalTrials":135,"cells":3891},{"EARLY_PHASE1":3892,"PHASE1":3894,"PHASE2":3896,"PHASE3":3902,"PHASE4":3904,"NA":3906},{"trials":3893,"activeCount":95},[],{"trials":3895,"activeCount":95},[],{"trials":3897,"activeCount":95},[3898],{"nctId":3856,"briefTitle":3857,"status":101,"phases":3899,"primaryCompletion":3859,"completion":3859,"start":3860,"enrollment":3861,"conditions":3900,"interventions":3901},[86],[15],[3847,3864,3865],{"trials":3903,"activeCount":95},[],{"trials":3905,"activeCount":95},[],{"trials":3907,"activeCount":95},[],{"intervention":3909,"totalTrials":135,"cells":3910},"Low Dose Rifaximin ER",{"EARLY_PHASE1":3911,"PHASE1":3913,"PHASE2":3915,"PHASE3":3930,"PHASE4":3932,"NA":3934},{"trials":3912,"activeCount":95},[],{"trials":3914,"activeCount":95},[],{"trials":3916,"activeCount":95},[3917],{"nctId":3918,"briefTitle":3919,"status":101,"phases":3920,"primaryCompletion":3921,"completion":3921,"start":3922,"enrollment":3923,"conditions":3924,"interventions":3926},"NCT05098028","Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease",[86],"2023-09-04","2022-03-22",44,[3925],"Sickle Cell Disease",[3909,3927,3928,3929],"Low Dose Rifaximin DER","High Dose Rifaximin ER","High Dose Rifaximin DER",{"trials":3931,"activeCount":95},[],{"trials":3933,"activeCount":95},[],{"trials":3935,"activeCount":95},[],{"intervention":3927,"totalTrials":135,"cells":3937},{"EARLY_PHASE1":3938,"PHASE1":3940,"PHASE2":3942,"PHASE3":3948,"PHASE4":3950,"NA":3952},{"trials":3939,"activeCount":95},[],{"trials":3941,"activeCount":95},[],{"trials":3943,"activeCount":95},[3944],{"nctId":3918,"briefTitle":3919,"status":101,"phases":3945,"primaryCompletion":3921,"completion":3921,"start":3922,"enrollment":3923,"conditions":3946,"interventions":3947},[86],[3925],[3909,3927,3928,3929],{"trials":3949,"activeCount":95},[],{"trials":3951,"activeCount":95},[],{"trials":3953,"activeCount":95},[],{"intervention":3928,"totalTrials":135,"cells":3955},{"EARLY_PHASE1":3956,"PHASE1":3958,"PHASE2":3960,"PHASE3":3966,"PHASE4":3968,"NA":3970},{"trials":3957,"activeCount":95},[],{"trials":3959,"activeCount":95},[],{"trials":3961,"activeCount":95},[3962],{"nctId":3918,"briefTitle":3919,"status":101,"phases":3963,"primaryCompletion":3921,"completion":3921,"start":3922,"enrollment":3923,"conditions":3964,"interventions":3965},[86],[3925],[3909,3927,3928,3929],{"trials":3967,"activeCount":95},[],{"trials":3969,"activeCount":95},[],{"trials":3971,"activeCount":95},[],{"intervention":3929,"totalTrials":135,"cells":3973},{"EARLY_PHASE1":3974,"PHASE1":3976,"PHASE2":3978,"PHASE3":3984,"PHASE4":3986,"NA":3988},{"trials":3975,"activeCount":95},[],{"trials":3977,"activeCount":95},[],{"trials":3979,"activeCount":95},[3980],{"nctId":3918,"briefTitle":3919,"status":101,"phases":3981,"primaryCompletion":3921,"completion":3921,"start":3922,"enrollment":3923,"conditions":3982,"interventions":3983},[86],[3925],[3909,3927,3928,3929],{"trials":3985,"activeCount":95},[],{"trials":3987,"activeCount":95},[],{"trials":3989,"activeCount":95},[],{"intervention":1393,"totalTrials":135,"cells":3991},{"EARLY_PHASE1":3992,"PHASE1":3994,"PHASE2":3996,"PHASE3":4002,"PHASE4":4004,"NA":4006},{"trials":3993,"activeCount":95},[],{"trials":3995,"activeCount":95},[],{"trials":3997,"activeCount":95},[3998],{"nctId":1385,"briefTitle":1386,"status":101,"phases":3999,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":4000,"interventions":4001},[86],[15],[1355,1393,1394,1395,1382],{"trials":4003,"activeCount":95},[],{"trials":4005,"activeCount":95},[],{"trials":4007,"activeCount":95},[],{"intervention":1394,"totalTrials":135,"cells":4009},{"EARLY_PHASE1":4010,"PHASE1":4012,"PHASE2":4014,"PHASE3":4020,"PHASE4":4022,"NA":4024},{"trials":4011,"activeCount":95},[],{"trials":4013,"activeCount":95},[],{"trials":4015,"activeCount":95},[4016],{"nctId":1385,"briefTitle":1386,"status":101,"phases":4017,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":4018,"interventions":4019},[86],[15],[1355,1393,1394,1395,1382],{"trials":4021,"activeCount":95},[],{"trials":4023,"activeCount":95},[],{"trials":4025,"activeCount":95},[],{"intervention":1395,"totalTrials":135,"cells":4027},{"EARLY_PHASE1":4028,"PHASE1":4030,"PHASE2":4032,"PHASE3":4038,"PHASE4":4040,"NA":4042},{"trials":4029,"activeCount":95},[],{"trials":4031,"activeCount":95},[],{"trials":4033,"activeCount":95},[4034],{"nctId":1385,"briefTitle":1386,"status":101,"phases":4035,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":4036,"interventions":4037},[86],[15],[1355,1393,1394,1395,1382],{"trials":4039,"activeCount":95},[],{"trials":4041,"activeCount":95},[],{"trials":4043,"activeCount":95},[],{"intervention":1647,"totalTrials":135,"cells":4045},{"EARLY_PHASE1":4046,"PHASE1":4048,"PHASE2":4050,"PHASE3":4056,"PHASE4":4058,"NA":4060},{"trials":4047,"activeCount":95},[],{"trials":4049,"activeCount":95},[],{"trials":4051,"activeCount":95},[4052],{"nctId":1639,"briefTitle":1640,"status":101,"phases":4053,"primaryCompletion":1642,"completion":1643,"start":889,"enrollment":1644,"conditions":4054,"interventions":4055},[86],[15],[1622,1647,1648,1649],{"trials":4057,"activeCount":95},[],{"trials":4059,"activeCount":95},[],{"trials":4061,"activeCount":95},[],{"intervention":1648,"totalTrials":135,"cells":4063},{"EARLY_PHASE1":4064,"PHASE1":4066,"PHASE2":4068,"PHASE3":4074,"PHASE4":4076,"NA":4078},{"trials":4065,"activeCount":95},[],{"trials":4067,"activeCount":95},[],{"trials":4069,"activeCount":95},[4070],{"nctId":1639,"briefTitle":1640,"status":101,"phases":4071,"primaryCompletion":1642,"completion":1643,"start":889,"enrollment":1644,"conditions":4072,"interventions":4073},[86],[15],[1622,1647,1648,1649],{"trials":4075,"activeCount":95},[],{"trials":4077,"activeCount":95},[],{"trials":4079,"activeCount":95},[],{"intervention":1649,"totalTrials":135,"cells":4081},{"EARLY_PHASE1":4082,"PHASE1":4084,"PHASE2":4086,"PHASE3":4092,"PHASE4":4094,"NA":4096},{"trials":4083,"activeCount":95},[],{"trials":4085,"activeCount":95},[],{"trials":4087,"activeCount":95},[4088],{"nctId":1639,"briefTitle":1640,"status":101,"phases":4089,"primaryCompletion":1642,"completion":1643,"start":889,"enrollment":1644,"conditions":4090,"interventions":4091},[86],[15],[1622,1647,1648,1649],{"trials":4093,"activeCount":95},[],{"trials":4095,"activeCount":95},[],{"trials":4097,"activeCount":95},[],{"intervention":4099,"totalTrials":135,"cells":4100},"SP-304 0.3 mg",{"EARLY_PHASE1":4101,"PHASE1":4103,"PHASE2":4105,"PHASE3":4117,"PHASE4":4119,"NA":4121},{"trials":4102,"activeCount":95},[],{"trials":4104,"activeCount":95},[],{"trials":4106,"activeCount":95},[4107],{"nctId":4108,"briefTitle":4109,"status":101,"phases":4110,"primaryCompletion":731,"completion":731,"start":4111,"enrollment":3135,"conditions":4112,"interventions":4113},"NCT01053962","SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation",[86],"2010-03",[28],[4099,4114,4115,4116],"SP-304 1.0 mg","SP-304 3.0 mg","SP-304 9.0 mg",{"trials":4118,"activeCount":95},[],{"trials":4120,"activeCount":95},[],{"trials":4122,"activeCount":95},[],{"intervention":4114,"totalTrials":135,"cells":4124},{"EARLY_PHASE1":4125,"PHASE1":4127,"PHASE2":4129,"PHASE3":4135,"PHASE4":4137,"NA":4139},{"trials":4126,"activeCount":95},[],{"trials":4128,"activeCount":95},[],{"trials":4130,"activeCount":95},[4131],{"nctId":4108,"briefTitle":4109,"status":101,"phases":4132,"primaryCompletion":731,"completion":731,"start":4111,"enrollment":3135,"conditions":4133,"interventions":4134},[86],[28],[4099,4114,4115,4116],{"trials":4136,"activeCount":95},[],{"trials":4138,"activeCount":95},[],{"trials":4140,"activeCount":95},[],{"intervention":4115,"totalTrials":135,"cells":4142},{"EARLY_PHASE1":4143,"PHASE1":4145,"PHASE2":4147,"PHASE3":4153,"PHASE4":4155,"NA":4157},{"trials":4144,"activeCount":95},[],{"trials":4146,"activeCount":95},[],{"trials":4148,"activeCount":95},[4149],{"nctId":4108,"briefTitle":4109,"status":101,"phases":4150,"primaryCompletion":731,"completion":731,"start":4111,"enrollment":3135,"conditions":4151,"interventions":4152},[86],[28],[4099,4114,4115,4116],{"trials":4154,"activeCount":95},[],{"trials":4156,"activeCount":95},[],{"trials":4158,"activeCount":95},[],{"intervention":4116,"totalTrials":135,"cells":4160},{"EARLY_PHASE1":4161,"PHASE1":4163,"PHASE2":4165,"PHASE3":4171,"PHASE4":4173,"NA":4175},{"trials":4162,"activeCount":95},[],{"trials":4164,"activeCount":95},[],{"trials":4166,"activeCount":95},[4167],{"nctId":4108,"briefTitle":4109,"status":101,"phases":4168,"primaryCompletion":731,"completion":731,"start":4111,"enrollment":3135,"conditions":4169,"interventions":4170},[86],[28],[4099,4114,4115,4116],{"trials":4172,"activeCount":95},[],{"trials":4174,"activeCount":95},[],{"trials":4176,"activeCount":95},[],{"intervention":3150,"totalTrials":135,"cells":4178},{"EARLY_PHASE1":4179,"PHASE1":4181,"PHASE2":4183,"PHASE3":4189,"PHASE4":4191,"NA":4193},{"trials":4180,"activeCount":95},[],{"trials":4182,"activeCount":95},[],{"trials":4184,"activeCount":95},[4185],{"nctId":3143,"briefTitle":3144,"status":101,"phases":4186,"primaryCompletion":732,"completion":2386,"start":3146,"enrollment":3147,"conditions":4187,"interventions":4188},[86],[18],[3150,3151,3125,3152],{"trials":4190,"activeCount":95},[],{"trials":4192,"activeCount":95},[],{"trials":4194,"activeCount":95},[],{"intervention":3151,"totalTrials":135,"cells":4196},{"EARLY_PHASE1":4197,"PHASE1":4199,"PHASE2":4201,"PHASE3":4207,"PHASE4":4209,"NA":4211},{"trials":4198,"activeCount":95},[],{"trials":4200,"activeCount":95},[],{"trials":4202,"activeCount":95},[4203],{"nctId":3143,"briefTitle":3144,"status":101,"phases":4204,"primaryCompletion":732,"completion":2386,"start":3146,"enrollment":3147,"conditions":4205,"interventions":4206},[86],[18],[3150,3151,3125,3152],{"trials":4208,"activeCount":95},[],{"trials":4210,"activeCount":95},[],{"trials":4212,"activeCount":95},[],{"intervention":3152,"totalTrials":135,"cells":4214},{"EARLY_PHASE1":4215,"PHASE1":4217,"PHASE2":4219,"PHASE3":4225,"PHASE4":4227,"NA":4229},{"trials":4216,"activeCount":95},[],{"trials":4218,"activeCount":95},[],{"trials":4220,"activeCount":95},[4221],{"nctId":3143,"briefTitle":3144,"status":101,"phases":4222,"primaryCompletion":732,"completion":2386,"start":3146,"enrollment":3147,"conditions":4223,"interventions":4224},[86],[18],[3150,3151,3125,3152],{"trials":4226,"activeCount":95},[],{"trials":4228,"activeCount":95},[],{"trials":4230,"activeCount":95},[],{"intervention":1911,"totalTrials":135,"cells":4232},{"EARLY_PHASE1":4233,"PHASE1":4235,"PHASE2":4237,"PHASE3":4243,"PHASE4":4245,"NA":4247},{"trials":4234,"activeCount":95},[],{"trials":4236,"activeCount":95},[],{"trials":4238,"activeCount":95},[4239],{"nctId":1905,"briefTitle":1906,"status":101,"phases":4240,"primaryCompletion":1027,"completion":831,"start":1203,"enrollment":1908,"conditions":4241,"interventions":4242},[86],[1880],[1911,1911,1911,1882],{"trials":4244,"activeCount":95},[],{"trials":4246,"activeCount":95},[],{"trials":4248,"activeCount":95},[],{"intervention":4250,"totalTrials":135,"cells":4251},"AMG 827 140",{"EARLY_PHASE1":4252,"PHASE1":4254,"PHASE2":4256,"PHASE3":4268,"PHASE4":4270,"NA":4272},{"trials":4253,"activeCount":95},[],{"trials":4255,"activeCount":95},[],{"trials":4257,"activeCount":95},[4258],{"nctId":4259,"briefTitle":4260,"status":600,"phases":4261,"primaryCompletion":1490,"completion":2282,"start":4262,"enrollment":4263,"conditions":4264,"interventions":4265},"NCT01516957","AMG 827 in Subjects With Psoriatic Arthritis",[86],"2011-10",168,[1472],[4250,4266,4267],"AMG 827 280","AMG 827 210",{"trials":4269,"activeCount":95},[],{"trials":4271,"activeCount":95},[],{"trials":4273,"activeCount":95},[],{"intervention":4266,"totalTrials":135,"cells":4275},{"EARLY_PHASE1":4276,"PHASE1":4278,"PHASE2":4280,"PHASE3":4286,"PHASE4":4288,"NA":4290},{"trials":4277,"activeCount":95},[],{"trials":4279,"activeCount":95},[],{"trials":4281,"activeCount":95},[4282],{"nctId":4259,"briefTitle":4260,"status":600,"phases":4283,"primaryCompletion":1490,"completion":2282,"start":4262,"enrollment":4263,"conditions":4284,"interventions":4285},[86],[1472],[4250,4266,4267],{"trials":4287,"activeCount":95},[],{"trials":4289,"activeCount":95},[],{"trials":4291,"activeCount":95},[],{"intervention":4267,"totalTrials":135,"cells":4293},{"EARLY_PHASE1":4294,"PHASE1":4296,"PHASE2":4298,"PHASE3":4304,"PHASE4":4306,"NA":4308},{"trials":4295,"activeCount":95},[],{"trials":4297,"activeCount":95},[],{"trials":4299,"activeCount":95},[4300],{"nctId":4259,"briefTitle":4260,"status":600,"phases":4301,"primaryCompletion":1490,"completion":2282,"start":4262,"enrollment":4263,"conditions":4302,"interventions":4303},[86],[1472],[4250,4266,4267],{"trials":4305,"activeCount":95},[],{"trials":4307,"activeCount":95},[],{"trials":4309,"activeCount":95},[],{"intervention":4311,"totalTrials":135,"cells":4312},"Tetrabenazine MR",{"EARLY_PHASE1":4313,"PHASE1":4315,"PHASE2":4317,"PHASE3":4329,"PHASE4":4331,"NA":4333},{"trials":4314,"activeCount":95},[],{"trials":4316,"activeCount":95},[],{"trials":4318,"activeCount":95},[4319],{"nctId":4320,"briefTitle":4321,"status":754,"phases":4322,"primaryCompletion":4323,"completion":4324,"start":4325,"enrollment":95,"conditions":4326,"interventions":4328},"NCT01133353","A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's Syndrome",[86],"2011-11","2011-12","2011-03",[4327],"Tourette's Syndrome",[4311],{"trials":4330,"activeCount":95},[],{"trials":4332,"activeCount":95},[],{"trials":4334,"activeCount":95},[],{"intervention":187,"totalTrials":135,"cells":4336},{"EARLY_PHASE1":4337,"PHASE1":4339,"PHASE2":4341,"PHASE3":4347,"PHASE4":4349,"NA":4351},{"trials":4338,"activeCount":95},[],{"trials":4340,"activeCount":95},[],{"trials":4342,"activeCount":95},[4343],{"nctId":177,"briefTitle":178,"status":101,"phases":4344,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":4345,"interventions":4346},[86],[18],[186,187,53,188],{"trials":4348,"activeCount":95},[],{"trials":4350,"activeCount":95},[],{"trials":4352,"activeCount":95},[],{"intervention":676,"totalTrials":135,"cells":4354},{"EARLY_PHASE1":4355,"PHASE1":4357,"PHASE2":4359,"PHASE3":4365,"PHASE4":4367,"NA":4369},{"trials":4356,"activeCount":95},[],{"trials":4358,"activeCount":95},[],{"trials":4360,"activeCount":95},[4361],{"nctId":670,"briefTitle":671,"status":101,"phases":4362,"primaryCompletion":113,"completion":113,"start":673,"enrollment":6,"conditions":4363,"interventions":4364},[86],[25],[630,676,677,658],{"trials":4366,"activeCount":95},[],{"trials":4368,"activeCount":95},[],{"trials":4370,"activeCount":95},[],{"intervention":677,"totalTrials":135,"cells":4372},{"EARLY_PHASE1":4373,"PHASE1":4375,"PHASE2":4377,"PHASE3":4383,"PHASE4":4385,"NA":4387},{"trials":4374,"activeCount":95},[],{"trials":4376,"activeCount":95},[],{"trials":4378,"activeCount":95},[4379],{"nctId":670,"briefTitle":671,"status":101,"phases":4380,"primaryCompletion":113,"completion":113,"start":673,"enrollment":6,"conditions":4381,"interventions":4382},[86],[25],[630,676,677,658],{"trials":4384,"activeCount":95},[],{"trials":4386,"activeCount":95},[],{"trials":4388,"activeCount":95},[],{"intervention":4390,"totalTrials":132,"cells":4391},"50 mg\u002FmL Virazole",{"EARLY_PHASE1":4392,"PHASE1":4394,"PHASE2":4415,"PHASE3":4417,"PHASE4":4419,"NA":4421},{"trials":4393,"activeCount":95},[],{"trials":4395,"activeCount":95},[4396,4406],{"nctId":4397,"briefTitle":4398,"status":754,"phases":4399,"primaryCompletion":4400,"completion":4400,"start":4401,"enrollment":95,"conditions":4402,"interventions":4404},"NCT04356677","Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2",[85],"2021-08","2021-05",[4403],"COVID19",[4390,4405],"100 mg\u002FmL Virazole",{"nctId":4407,"briefTitle":4408,"status":101,"phases":4409,"primaryCompletion":4410,"completion":4410,"start":4411,"enrollment":4412,"conditions":4413,"interventions":4414},"NCT04551768","Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19",[85],"2021-08-17","2021-02-10",51,[4403],[4390,4405],{"trials":4416,"activeCount":95},[],{"trials":4418,"activeCount":95},[],{"trials":4420,"activeCount":95},[],{"trials":4422,"activeCount":95},[],{"intervention":4405,"totalTrials":132,"cells":4424},{"EARLY_PHASE1":4425,"PHASE1":4427,"PHASE2":4437,"PHASE3":4439,"PHASE4":4441,"NA":4443},{"trials":4426,"activeCount":95},[],{"trials":4428,"activeCount":95},[4429,4433],{"nctId":4397,"briefTitle":4398,"status":754,"phases":4430,"primaryCompletion":4400,"completion":4400,"start":4401,"enrollment":95,"conditions":4431,"interventions":4432},[85],[4403],[4390,4405],{"nctId":4407,"briefTitle":4408,"status":101,"phases":4434,"primaryCompletion":4410,"completion":4410,"start":4411,"enrollment":4412,"conditions":4435,"interventions":4436},[85],[4403],[4390,4405],{"trials":4438,"activeCount":95},[],{"trials":4440,"activeCount":95},[],{"trials":4442,"activeCount":95},[],{"trials":4444,"activeCount":95},[],{"intervention":4446,"totalTrials":135,"cells":4447},"Rifaximin Novel Formulation",{"EARLY_PHASE1":4448,"PHASE1":4450,"PHASE2":4461,"PHASE3":4463,"PHASE4":4465,"NA":4467},{"trials":4449,"activeCount":95},[],{"trials":4451,"activeCount":95},[4452],{"nctId":4453,"briefTitle":4454,"status":101,"phases":4455,"primaryCompletion":4456,"completion":4456,"start":4457,"enrollment":4458,"conditions":4459,"interventions":4460},"NCT04529811","Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifaximin Formulations in Healthy Volunteers",[85],"2021-05-09","2020-09-24",124,[3029],[4446],{"trials":4462,"activeCount":95},[],{"trials":4464,"activeCount":95},[],{"trials":4466,"activeCount":95},[],{"trials":4468,"activeCount":95},[],{"intervention":3003,"totalTrials":135,"cells":4470},{"EARLY_PHASE1":4471,"PHASE1":4473,"PHASE2":4479,"PHASE3":4481,"PHASE4":4483,"NA":4485},{"trials":4472,"activeCount":95},[],{"trials":4474,"activeCount":95},[4475],{"nctId":2996,"briefTitle":2997,"status":101,"phases":4476,"primaryCompletion":2749,"completion":2749,"start":2999,"enrollment":11,"conditions":4477,"interventions":4478},[85],[3001],[3003,1299],{"trials":4480,"activeCount":95},[],{"trials":4482,"activeCount":95},[],{"trials":4484,"activeCount":95},[],{"trials":4486,"activeCount":95},[],{"intervention":4488,"totalTrials":135,"cells":4489},"Loteprednol Etabonate Ophthalmic Gel",{"EARLY_PHASE1":4490,"PHASE1":4492,"PHASE2":4502,"PHASE3":4504,"PHASE4":4506,"NA":4508},{"trials":4491,"activeCount":95},[],{"trials":4493,"activeCount":95},[4494],{"nctId":4495,"briefTitle":4496,"status":101,"phases":4497,"primaryCompletion":2283,"completion":3224,"start":4498,"enrollment":11,"conditions":4499,"interventions":4501},"NCT03063489","Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability",[85],"2015-02",[4500],"Eye Pain",[4488],{"trials":4503,"activeCount":95},[],{"trials":4505,"activeCount":95},[],{"trials":4507,"activeCount":95},[],{"trials":4509,"activeCount":95},[],{"intervention":4511,"totalTrials":135,"cells":4512},"SP-333",{"EARLY_PHASE1":4513,"PHASE1":4515,"PHASE2":4526,"PHASE3":4528,"PHASE4":4530,"NA":4532},{"trials":4514,"activeCount":95},[],{"trials":4516,"activeCount":95},[4517],{"nctId":4518,"briefTitle":4519,"status":101,"phases":4520,"primaryCompletion":4521,"completion":4521,"start":2473,"enrollment":4522,"conditions":4523,"interventions":4525},"NCT01705938","Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of SP-333 Tablets in Healthy Adult Subjects",[85],"2012-12",56,[4524],"Exposure",[4511],{"trials":4527,"activeCount":95},[],{"trials":4529,"activeCount":95},[],{"trials":4531,"activeCount":95},[],{"trials":4533,"activeCount":95},[],{"intervention":3138,"totalTrials":135,"cells":4535},{"EARLY_PHASE1":4536,"PHASE1":4538,"PHASE2":4544,"PHASE3":4546,"PHASE4":4548,"NA":4550},{"trials":4537,"activeCount":95},[],{"trials":4539,"activeCount":95},[4540],{"nctId":3132,"briefTitle":3133,"status":101,"phases":4541,"primaryCompletion":556,"completion":556,"start":1186,"enrollment":3135,"conditions":4542,"interventions":4543},[85],[18],[3138,3139,3125],{"trials":4545,"activeCount":95},[],{"trials":4547,"activeCount":95},[],{"trials":4549,"activeCount":95},[],{"trials":4551,"activeCount":95},[],{"intervention":3139,"totalTrials":135,"cells":4553},{"EARLY_PHASE1":4554,"PHASE1":4556,"PHASE2":4562,"PHASE3":4564,"PHASE4":4566,"NA":4568},{"trials":4555,"activeCount":95},[],{"trials":4557,"activeCount":95},[4558],{"nctId":3132,"briefTitle":3133,"status":101,"phases":4559,"primaryCompletion":556,"completion":556,"start":1186,"enrollment":3135,"conditions":4560,"interventions":4561},[85],[18],[3138,3139,3125],{"trials":4563,"activeCount":95},[],{"trials":4565,"activeCount":95},[],{"trials":4567,"activeCount":95},[],{"trials":4569,"activeCount":95},[],{"intervention":4571,"totalTrials":135,"cells":4572},"mesalamine",{"EARLY_PHASE1":4573,"PHASE1":4575,"PHASE2":4583,"PHASE3":4585,"PHASE4":4587,"NA":4589},{"trials":4574,"activeCount":95},[],{"trials":4576,"activeCount":95},[4577],{"nctId":4578,"briefTitle":4579,"status":101,"phases":4580,"primaryCompletion":800,"completion":1256,"start":800,"enrollment":513,"conditions":4581,"interventions":4582},"NCT00622375","PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers",[85],[33],[4571],{"trials":4584,"activeCount":95},[],{"trials":4586,"activeCount":95},[],{"trials":4588,"activeCount":95},[],{"trials":4590,"activeCount":95},[],{"intervention":4592,"totalTrials":135,"cells":4593},"Apriso 0.375G ER CAP",{"EARLY_PHASE1":4594,"PHASE1":4596,"PHASE2":4609,"PHASE3":4611,"PHASE4":4613,"NA":4615},{"trials":4595,"activeCount":95},[],{"trials":4597,"activeCount":95},[4598],{"nctId":4599,"briefTitle":4600,"status":101,"phases":4601,"primaryCompletion":4602,"completion":4603,"start":4604,"enrollment":4605,"conditions":4606,"interventions":4607},"NCT03327558","Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects",[85],"2017-06-23","2017-08-18","2017-05-15",60,[20],[4592,4608],"APRISO 375 mg extended-release",{"trials":4610,"activeCount":95},[],{"trials":4612,"activeCount":95},[],{"trials":4614,"activeCount":95},[],{"trials":4616,"activeCount":95},[],{"intervention":4608,"totalTrials":135,"cells":4618},{"EARLY_PHASE1":4619,"PHASE1":4621,"PHASE2":4627,"PHASE3":4629,"PHASE4":4631,"NA":4633},{"trials":4620,"activeCount":95},[],{"trials":4622,"activeCount":95},[4623],{"nctId":4599,"briefTitle":4600,"status":101,"phases":4624,"primaryCompletion":4602,"completion":4603,"start":4604,"enrollment":4605,"conditions":4625,"interventions":4626},[85],[20],[4592,4608],{"trials":4628,"activeCount":95},[],{"trials":4630,"activeCount":95},[],{"trials":4632,"activeCount":95},[],{"trials":4634,"activeCount":95},[],{"intervention":1300,"totalTrials":135,"cells":4636},{"EARLY_PHASE1":4637,"PHASE1":4639,"PHASE2":4645,"PHASE3":4647,"PHASE4":4649,"NA":4651},{"trials":4638,"activeCount":95},[],{"trials":4640,"activeCount":95},[4641],{"nctId":1293,"briefTitle":1294,"status":101,"phases":4642,"primaryCompletion":1224,"completion":1224,"start":1231,"enrollment":338,"conditions":4643,"interventions":4644},[85],[1297],[1277,1299,1300,1301],{"trials":4646,"activeCount":95},[],{"trials":4648,"activeCount":95},[],{"trials":4650,"activeCount":95},[],{"trials":4652,"activeCount":95},[],{"intervention":4654,"totalTrials":135,"cells":4655},"Moxifloxacin",{"EARLY_PHASE1":4656,"PHASE1":4658,"PHASE2":4670,"PHASE3":4672,"PHASE4":4674,"NA":4676},{"trials":4657,"activeCount":95},[],{"trials":4659,"activeCount":95},[4660],{"nctId":4661,"briefTitle":4662,"status":101,"phases":4663,"primaryCompletion":4664,"completion":1319,"start":4665,"enrollment":4666,"conditions":4667,"interventions":4668},"NCT01363323","Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization",[85],"2005-01","2004-11",546,[3029],[4669,4669,4669,4654],"Methylnaltrexone",{"trials":4671,"activeCount":95},[],{"trials":4673,"activeCount":95},[],{"trials":4675,"activeCount":95},[],{"trials":4677,"activeCount":95},[],{"intervention":4679,"totalTrials":135,"cells":4680},"MNTX",{"EARLY_PHASE1":4681,"PHASE1":4683,"PHASE2":4692,"PHASE3":4694,"PHASE4":4696,"NA":4698},{"trials":4682,"activeCount":95},[],{"trials":4684,"activeCount":95},[4685],{"nctId":4686,"briefTitle":4687,"status":101,"phases":4688,"primaryCompletion":1288,"completion":1288,"start":1345,"enrollment":513,"conditions":4689,"interventions":4691},"NCT01366352","Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets",[85],[4690],"Normal Volunteers",[4679,4679],{"trials":4693,"activeCount":95},[],{"trials":4695,"activeCount":95},[],{"trials":4697,"activeCount":95},[],{"trials":4699,"activeCount":95},[],{"intervention":646,"totalTrials":135,"cells":4701},{"EARLY_PHASE1":4702,"PHASE1":4704,"PHASE2":4710,"PHASE3":4712,"PHASE4":4714,"NA":4716},{"trials":4703,"activeCount":95},[],{"trials":4705,"activeCount":95},[4706],{"nctId":638,"briefTitle":639,"status":101,"phases":4707,"primaryCompletion":641,"completion":181,"start":642,"enrollment":643,"conditions":4708,"interventions":4709},[85],[18],[630,646,188,647],{"trials":4711,"activeCount":95},[],{"trials":4713,"activeCount":95},[],{"trials":4715,"activeCount":95},[],{"trials":4717,"activeCount":95},[],{"intervention":1370,"totalTrials":135,"cells":4719},{"EARLY_PHASE1":4720,"PHASE1":4722,"PHASE2":4728,"PHASE3":4730,"PHASE4":4732,"NA":4734},{"trials":4721,"activeCount":95},[],{"trials":4723,"activeCount":95},[4724],{"nctId":1362,"briefTitle":1363,"status":101,"phases":4725,"primaryCompletion":1365,"completion":1365,"start":1366,"enrollment":1367,"conditions":4726,"interventions":4727},[85],[15],[1355,1370],{"trials":4729,"activeCount":95},[],{"trials":4731,"activeCount":95},[],{"trials":4733,"activeCount":95},[],{"trials":4735,"activeCount":95},[],{"intervention":4737,"totalTrials":135,"cells":4738},"Oral methylnaltrexone",{"EARLY_PHASE1":4739,"PHASE1":4741,"PHASE2":4752,"PHASE3":4754,"PHASE4":4756,"NA":4758},{"trials":4740,"activeCount":95},[],{"trials":4742,"activeCount":95},[4743],{"nctId":4744,"briefTitle":4745,"status":101,"phases":4746,"primaryCompletion":1888,"completion":1888,"start":4747,"enrollment":745,"conditions":4748,"interventions":4750},"NCT01366339","Tolerance and Pharmacokinetics Study of MNTX Tablets",[85],"2003-10",[4749],"Normal Healthy Volunteers",[4737,4751],"Oral placebo",{"trials":4753,"activeCount":95},[],{"trials":4755,"activeCount":95},[],{"trials":4757,"activeCount":95},[],{"trials":4759,"activeCount":95},[],{"intervention":4751,"totalTrials":135,"cells":4761},{"EARLY_PHASE1":4762,"PHASE1":4764,"PHASE2":4770,"PHASE3":4772,"PHASE4":4774,"NA":4776},{"trials":4763,"activeCount":95},[],{"trials":4765,"activeCount":95},[4766],{"nctId":4744,"briefTitle":4745,"status":101,"phases":4767,"primaryCompletion":1888,"completion":1888,"start":4747,"enrollment":745,"conditions":4768,"interventions":4769},[85],[4749],[4737,4751],{"trials":4771,"activeCount":95},[],{"trials":4773,"activeCount":95},[],{"trials":4775,"activeCount":95},[],{"trials":4777,"activeCount":95},[],{"intervention":4779,"totalTrials":135,"cells":4780},"50 mg\u002FmL Virazole Inhalant Product",{"EARLY_PHASE1":4781,"PHASE1":4783,"PHASE2":4795,"PHASE3":4797,"PHASE4":4799,"NA":4801},{"trials":4782,"activeCount":95},[],{"trials":4784,"activeCount":95},[4785],{"nctId":4786,"briefTitle":4787,"status":101,"phases":4788,"primaryCompletion":4789,"completion":4789,"start":4790,"enrollment":4791,"conditions":4792,"interventions":4793},"NCT05229510","Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers",[85],"2021-07-12","2021-03-12",32,[33],[4779,4794],"100 mg\u002FmL Virazole Inhalant Product",{"trials":4796,"activeCount":95},[],{"trials":4798,"activeCount":95},[],{"trials":4800,"activeCount":95},[],{"trials":4802,"activeCount":95},[],{"intervention":4794,"totalTrials":135,"cells":4804},{"EARLY_PHASE1":4805,"PHASE1":4807,"PHASE2":4813,"PHASE3":4815,"PHASE4":4817,"NA":4819},{"trials":4806,"activeCount":95},[],{"trials":4808,"activeCount":95},[4809],{"nctId":4786,"briefTitle":4787,"status":101,"phases":4810,"primaryCompletion":4789,"completion":4789,"start":4790,"enrollment":4791,"conditions":4811,"interventions":4812},[85],[33],[4779,4794],{"trials":4814,"activeCount":95},[],{"trials":4816,"activeCount":95},[],{"trials":4818,"activeCount":95},[],{"trials":4820,"activeCount":95},[],{"intervention":4669,"totalTrials":4822,"cells":4823},11,{"EARLY_PHASE1":4824,"PHASE1":4826,"PHASE2":4856,"PHASE3":4858,"PHASE4":4893,"NA":4909},{"trials":4825,"activeCount":95},[],{"trials":4827,"activeCount":95},[4828,4837,4841,4849],{"nctId":4829,"briefTitle":4830,"status":101,"phases":4831,"primaryCompletion":4832,"completion":4832,"start":1177,"enrollment":4833,"conditions":4834,"interventions":4835},"NCT01366365","Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide",[85],"2006-11",28,[1297],[4836],"methylnaltrexone",{"nctId":4661,"briefTitle":4662,"status":101,"phases":4838,"primaryCompletion":4664,"completion":1319,"start":4665,"enrollment":4666,"conditions":4839,"interventions":4840},[85],[3029],[4669,4669,4669,4654],{"nctId":4842,"briefTitle":4843,"status":101,"phases":4844,"primaryCompletion":4845,"completion":4845,"start":1028,"enrollment":4846,"conditions":4847,"interventions":4848},"NCT01366378","Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX",[85],"2007-02",18,[735],[4836],{"nctId":4850,"briefTitle":4851,"status":101,"phases":4852,"primaryCompletion":4664,"completion":591,"start":1288,"enrollment":4791,"conditions":4853,"interventions":4855},"NCT01367509","Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function",[85],[4854],"Renal Impairment",[4669],{"trials":4857,"activeCount":95},[],{"trials":4859,"activeCount":95},[4860,4869,4877,4886],{"nctId":4861,"briefTitle":4862,"status":101,"phases":4863,"primaryCompletion":4864,"completion":4864,"start":4865,"enrollment":384,"conditions":4866,"interventions":4868},"NCT00401375","Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)",[87],"2008-02-29","2006-10-31",[4867],"Post-Operative Ileus (POI)",[4669],{"nctId":4870,"briefTitle":4871,"status":101,"phases":4872,"completion":2155,"start":566,"enrollment":4873,"conditions":4874,"interventions":4876},"NCT00387309","Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus",[87],495,[4875],"Post Operative Bowel Dysfunction",[4669],{"nctId":4878,"briefTitle":4879,"status":101,"phases":4880,"primaryCompletion":4881,"completion":4881,"start":4882,"enrollment":4883,"conditions":4884,"interventions":4885},"NCT01186770","A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain",[87],"2011-09-08","2010-09-01",804,[779],[4669],{"nctId":4887,"briefTitle":4888,"status":101,"phases":4889,"primaryCompletion":2658,"completion":2658,"start":1053,"enrollment":4890,"conditions":4891,"interventions":4892},"NCT00936884","Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation",[87],50,[22],[4669],{"trials":4894,"activeCount":95},[4895,4902],{"nctId":4896,"briefTitle":4897,"status":101,"phases":4898,"primaryCompletion":4899,"completion":4899,"start":2411,"enrollment":546,"conditions":4900,"interventions":4901},"NCT00672477","Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness",[88],"2013-02",[779],[4669],{"nctId":4903,"briefTitle":4904,"status":754,"phases":4905,"primaryCompletion":555,"completion":555,"start":4906,"enrollment":95,"conditions":4907,"interventions":4908},"NCT00858754","Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects",[88],"2009-03",[779],[4836],{"trials":4910,"activeCount":95},[4911],{"nctId":4912,"briefTitle":4913,"status":101,"phases":4914,"primaryCompletion":4915,"completion":4915,"start":4916,"enrollment":822,"conditions":4917,"interventions":4918},"NCT01368562","Compassionate Use Study of Methylnaltrexone",[89],"2008-06-02","2003-01-24",[747],[4669],{"intervention":2662,"totalTrials":4822,"cells":4920},{"EARLY_PHASE1":4921,"PHASE1":4923,"PHASE2":4925,"PHASE3":4955,"PHASE4":5009,"NA":5011},{"trials":4922,"activeCount":95},[],{"trials":4924,"activeCount":95},[],{"trials":4926,"activeCount":95},[4927,4938,4945],{"nctId":4928,"briefTitle":4929,"status":101,"phases":4930,"primaryCompletion":4931,"completion":4932,"start":4933,"enrollment":4934,"conditions":4935,"interventions":4937},"NCT01722318","The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)",[86],"2014-04","2014-10","2012-11",428,[4936],"Irritable Bowel Syndrome Characterized by Constipation",[2662],{"nctId":4939,"briefTitle":4940,"status":101,"phases":4941,"primaryCompletion":4942,"completion":4942,"start":181,"enrollment":4458,"conditions":4943,"interventions":4944},"NCT03120520","An Efficacy and Safety Study of Plecanatide in Adolescents 12 to \u003C18 Years of Age With Chronic Idiopathic Constipation",[86],"2018-09-07",[28],[2662],{"nctId":4946,"briefTitle":4947,"status":101,"phases":4948,"primaryCompletion":4949,"completion":4949,"start":4950,"enrollment":4951,"conditions":4952,"interventions":4954},"NCT03596905","Efficacy and Safety of Plecanatide in Children 6 to \u003C18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)",[86],"2024-11-25","2018-06-30",218,[4953],"Irritable Bowel Syndrome With Constipation",[2662],{"trials":4956,"activeCount":95},[4957,4965,4972,4982,4988,4992,5000],{"nctId":4958,"briefTitle":4959,"status":101,"phases":4960,"primaryCompletion":1633,"completion":4961,"start":2657,"enrollment":4962,"conditions":4963,"interventions":4964},"NCT02493452","Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)",[87],"2017-02",1135,[4936],[2662],{"nctId":4966,"briefTitle":4967,"status":101,"phases":4968,"primaryCompletion":2283,"completion":3224,"start":4931,"enrollment":4969,"conditions":4970,"interventions":4971},"NCT02122471","12-Week Study of Plecanatide for CIC (The National CIC3 Study)",[87],1410,[28],[2662],{"nctId":4973,"briefTitle":4974,"status":101,"phases":4975,"primaryCompletion":4976,"completion":4977,"start":4978,"enrollment":4979,"conditions":4980,"interventions":4981},"NCT01919697","Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)",[87],"2016-01","2016-03","2013-08",2370,[28],[2662],{"nctId":4983,"briefTitle":4929,"status":101,"phases":4984,"primaryCompletion":641,"completion":4961,"start":104,"enrollment":4985,"conditions":4986,"interventions":4987},"NCT02387359",[87],1054,[4936],[2662],{"nctId":2654,"briefTitle":2655,"status":101,"phases":4989,"primaryCompletion":642,"completion":2657,"start":2658,"enrollment":2659,"conditions":4990,"interventions":4991},[87],[28],[2662,2643],{"nctId":4993,"briefTitle":4994,"status":101,"phases":4995,"primaryCompletion":4521,"completion":4521,"start":4262,"enrollment":4996,"conditions":4997,"interventions":4998},"NCT01429987","The Plecanatide Chronic Idiopathic Constipation (CIC) Study",[86,87],951,[28],[4999],"plecanatide",{"nctId":5001,"briefTitle":5002,"status":101,"phases":5003,"primaryCompletion":5004,"completion":5005,"start":4976,"enrollment":5006,"conditions":5007,"interventions":5008},"NCT02706483","Long Term Safety Study of Plecanatide",[87],"2017-05","2017-06",2272,[528],[2662],{"trials":5010,"activeCount":95},[],{"trials":5012,"activeCount":95},[5013],{"nctId":5014,"briefTitle":5015,"status":101,"phases":5016,"primaryCompletion":5017,"completion":5017,"start":5018,"enrollment":26,"conditions":5019,"interventions":5020},"NCT03551873","A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®",[],"2018-12-14","2018-06-21",[28],[2662],{"intervention":5022,"totalTrials":132,"cells":5023},"Fipamezole ODT",{"EARLY_PHASE1":5024,"PHASE1":5026,"PHASE2":5028,"PHASE3":5030,"PHASE4":5032,"NA":5034},{"trials":5025,"activeCount":95},[],{"trials":5027,"activeCount":95},[],{"trials":5029,"activeCount":95},[],{"trials":5031,"activeCount":95},[],{"trials":5033,"activeCount":95},[],{"trials":5035,"activeCount":95},[5036,5044],{"nctId":5037,"briefTitle":5038,"status":101,"phases":5039,"primaryCompletion":3834,"completion":3834,"start":732,"enrollment":1337,"conditions":5040,"interventions":5042},"NCT01149811","A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease",[],[5041],"Parkinson's Disease",[5022,5043],"Fipamezole ODT Cohort 2",{"nctId":5045,"briefTitle":5046,"status":101,"phases":5047,"primaryCompletion":3834,"completion":3834,"start":2817,"enrollment":5048,"conditions":5049,"interventions":5050},"NCT01140841","A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa",[],40,[5041],[5022],{"intervention":5043,"totalTrials":135,"cells":5052},{"EARLY_PHASE1":5053,"PHASE1":5055,"PHASE2":5057,"PHASE3":5059,"PHASE4":5061,"NA":5063},{"trials":5054,"activeCount":95},[],{"trials":5056,"activeCount":95},[],{"trials":5058,"activeCount":95},[],{"trials":5060,"activeCount":95},[],{"trials":5062,"activeCount":95},[],{"trials":5064,"activeCount":95},[5065],{"nctId":5037,"briefTitle":5038,"status":101,"phases":5066,"primaryCompletion":3834,"completion":3834,"start":732,"enrollment":1337,"conditions":5067,"interventions":5068},[],[5041],[5022,5043],{"intervention":5070,"totalTrials":135,"cells":5071},"Pergolide",{"EARLY_PHASE1":5072,"PHASE1":5074,"PHASE2":5076,"PHASE3":5078,"PHASE4":5080,"NA":5082},{"trials":5073,"activeCount":95},[],{"trials":5075,"activeCount":95},[],{"trials":5077,"activeCount":95},[],{"trials":5079,"activeCount":95},[],{"trials":5081,"activeCount":95},[],{"trials":5083,"activeCount":95},[5084],{"nctId":5085,"briefTitle":5086,"status":5087,"phases":5088,"conditions":5089,"interventions":5091},"NCT00624741","Compassionate Use Study of Pergolide in Patients With Parkinson's Disease","NO_LONGER_AVAILABLE",[],[5090],"Parkinson Disease",[5070]]